<SEC-DOCUMENT>0000886163-15-000060.txt : 20150511
<SEC-HEADER>0000886163-15-000060.hdr.sgml : 20150511
<ACCEPTANCE-DATETIME>20150511083400
ACCESSION NUMBER:		0000886163-15-000060
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150511
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150511
DATE AS OF CHANGE:		20150511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770160744
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33093
		FILM NUMBER:		15849000

	BUSINESS ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD
		STREET 2:		SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD
		STREET 2:		SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ligand-8xkq12015earningsre.htm
<DESCRIPTION>8-K_Q12015EARNINGSRELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Ligand-8-K Q1 2015 earnings release  </title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s1F2E16BBD04252759107C03E599BE5F0"></a><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;font-weight:bold;">______________</font></div><div style="line-height:120%;padding-top:21px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">FORM 8&#8209;K</font></div><div style="line-height:120%;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;font-weight:bold;">______________</font></div><div style="line-height:120%;padding-top:21px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Report (Date of earliest event reported): May 11, 2015</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:8pt;">(Exact Name of Registrant as Specified in Its Charter)</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;font-weight:bold;">______________</font></div><div style="line-height:120%;padding-top:21px;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:624px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="312px"></td><td width="312px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">77-0160744</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(State or other jurisdiction of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11119 North Torrey Pines Road, Suite 200</font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">La Jolla, CA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">92037</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Zip Code)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(858)&#160;550-7500</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant&#8217;s Telephone Number, Including Area Code)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">N/A</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425) </font></div><div style="line-height:180%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></div><div style="line-height:180%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></div><div style="line-height:180%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><br><hr style="page-break-after:always"><a name="s1F2E16BBD04252759107C03E599BE5F0"></a><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1.01&#160; Entry into a Material Definitive Agreement. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 8, 2015, we entered into a Royalty Stream and Milestone Payments Purchase Agreement with Selexis SA, a privately held life sciences company headquartered in Switzerland, to acquire a portfolio of possible future royalty and milestone payment rights based on over 15 Selexis commercial license agreement programs with various pharmaceutical-company counterparties.&#160; In return, we paid Selexis $4.0 million in cash.&#160; The more than 15 programs that are the subject of this transaction are based on Selexis&#8217; technology platform for cell line development and scale-up to manufacturing of therapeutic proteins and relate to pre-commercialized drugs that are currently being developed, and which should require no funding or technological support from Ligand.&#160; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.02  Results of Operations and Financial Condition. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 11, 2015 Ligand Pharmaceuticals Incorporated (the &#8220;Company&#8221;) issued a press release announcing its financial results for the three months ended March 31, 2015.  A copy of this press release is furnished herewith as Exhibit 99.1. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act, except as expressly set forth by specific reference in such a filing.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01  Financial Statements and Exhibits.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Exhibits.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="14%"></td><td width="86%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated May 11, 2015</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><hr style="page-break-after:always"><a name="s1F2E16BBD04252759107C03E599BE5F0"></a><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:26px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-bottom:48px;text-align:left;padding-left:240px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:25px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.94017094017094%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="31%"></td><td width="69%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LIGAND PHARMACEUTICALS INCORPORATED</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 11, 2015</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:   </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Nishan de Silva</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;<br>Name:   Nishan de Silva <br>Title:   Vice President, Finance and Strategy and Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><br><hr style="page-break-after:always"><a name="s1F2E16BBD04252759107C03E599BE5F0"></a><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="14%"></td><td width="86%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated May 11, 2015</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q12015earningsrelease.htm
<DESCRIPTION>EXHIBIT 99.1_Q12015EARNINGSRELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Q1 2015 Earnings Release  </title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s0C0C47A3C9E650F991866C0E8F35B104"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;"><img src="ligandlogoa03a01a01a01.jpg" style="height:69px;width:196px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:588px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="360px"></td><td width="228px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contacts:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ligand Pharmaceuticals Incorporated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">LHA</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Todd Pettingill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bruce Voss</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">investors@ligand.com</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">bvoss@lhai.com</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(858) 550-7500</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(310) 691-7100</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ligand Reports First Quarter 2015 Financial Results</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Conference Call Begins at 9:00 a.m. Eastern Time Today</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SAN DIEGO (May 11, 2015) - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)</font><font style="font-family:inherit;font-size:11pt;">&#32;today reported financial results for the three months ended March 31, 2015, and provided an operating forecast and program updates.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Financial highlights for the first quarter of 2015 include: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Total revenues were </font><font style="font-family:inherit;font-size:11pt;">$14.6 million</font><font style="font-family:inherit;font-size:11pt;">&#32;and royalty revenues were </font><font style="font-family:inherit;font-size:11pt;">$10.3 million</font><font style="font-family:inherit;font-size:11pt;">, an increase of </font><font style="font-family:inherit;font-size:11pt;">31%</font><font style="font-family:inherit;font-size:11pt;">&#32;compared with the first quarter of 2014.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Adjusted EPS was </font><font style="font-family:inherit;font-size:11pt;">$0.33</font><font style="font-family:inherit;font-size:11pt;">&#32;and GAAP EPS was </font><font style="font-family:inherit;font-size:11pt;">$0.04</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The company generated operating cash of $7.6 million, a significant increase over $2.6 million of operating cash generated in the first quarter of 2014</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A description of adjusted calculations and reconciliation to comparable GAAP financial measures is provided in the accompanying table titled &#8220;Adjusted Financial Measures.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;First quarter financial results feature continued strong growth in royalty revenues from both of our lead commercial assets, Promacta&#8482; and Kyprolis&#174; and strong growth in operating cash flow,&#8221; said John Higgins, President and Chief Executive Officer of Ligand.  &#8220;Our growing roster of partners made important clinical and regulatory progress with many of our programs, both in the U.S. and in Europe and including orphan and large-market indications.  Notably, Promacta has now transitioned from GSK to the highly capable stewardship of Novartis, and Amgen reported favorable clinical trial results with Kyprolis in a head-to-head comparison versus Velcade&#174; in patients with relapsed multiple myeloma. We also marked the successful IPO of a key partner and acquired a portfolio of royalty bearing programs. The team at Ligand is executing extremely well and we are very pleased with our performance as we move into mid-2015.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">First Quarter 2015 Financial Results</font></div><div style="line-height:120%;padding-bottom:6px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Total revenues for the first quarter of 2015 were </font><font style="font-family:inherit;font-size:11pt;">$14.6 million</font><font style="font-family:inherit;font-size:11pt;">, compared with </font><font style="font-family:inherit;font-size:11pt;">$16.0 million</font><font style="font-family:inherit;font-size:11pt;">&#32;for the same period in 2014.  Royalty revenues increased </font><font style="font-family:inherit;font-size:11pt;">31%</font><font style="font-family:inherit;font-size:11pt;">&#32;to </font><font style="font-family:inherit;font-size:11pt;">$10.3 million</font><font style="font-family:inherit;font-size:11pt;">&#32;from </font><font style="font-family:inherit;font-size:11pt;">$7.9 million</font><font style="font-family:inherit;font-size:11pt;">&#32;for the same period in 2014 primarily due to higher royalties from Promacta&#8482; and Kyprolis&#174;.  Material sales were </font><font style="font-family:inherit;font-size:11pt;">$3.7 million</font><font style="font-family:inherit;font-size:11pt;">&#32;compared with </font><font style="font-family:inherit;font-size:11pt;">$5.7 million</font><font style="font-family:inherit;font-size:11pt;">&#32;for the same period in 2014 due to the timing of Captisol purchases for use in clinical trials.  Collaborative research and development and other revenues were </font><font style="font-family:inherit;font-size:11pt;">$0.6 million</font><font style="font-family:inherit;font-size:11pt;">&#32;compared with </font><font style="font-family:inherit;font-size:11pt;">$2.4 million</font><font style="font-family:inherit;font-size:11pt;">&#32;for the same period in 2014 due primarily to significant milestones earned in the first quarter of 2014 from Merck for approval of Noxafil&#174; and from Amgen for a Kyprolis sales milestone.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Cost of goods sold decreased to </font><font style="font-family:inherit;font-size:11pt;">$1.1 million</font><font style="font-family:inherit;font-size:11pt;">&#32;for the first quarter of 2015 from </font><font style="font-family:inherit;font-size:11pt;">$2.5 million</font><font style="font-family:inherit;font-size:11pt;">&#32;for the same period in 2014, as a result of lower material sales.  Research and development expenses were </font><font style="font-family:inherit;font-size:11pt;">$4.0 million</font><font style="font-family:inherit;font-size:11pt;">&#32;compared with </font><font style="font-family:inherit;font-size:11pt;">$3.1 million</font><font style="font-family:inherit;font-size:11pt;">&#32;for the same period of 2014.  The increase was primarily due to costs associated with funding internal </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><a name="s0C0C47A3C9E650F991866C0E8F35B104"></a><br><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">development programs.  General and administrative expenses for the first quarter of 2015 were </font><font style="font-family:inherit;font-size:11pt;">$6.0 million</font><font style="font-family:inherit;font-size:11pt;">, compared with </font><font style="font-family:inherit;font-size:11pt;">$5.1 million</font><font style="font-family:inherit;font-size:11pt;">&#32;for the same period in 2014. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Net income for the first quarter of 2015 was </font><font style="font-family:inherit;font-size:11pt;">$0.8 million</font><font style="font-family:inherit;font-size:11pt;">, or </font><font style="font-family:inherit;font-size:11pt;">$0.04</font><font style="font-family:inherit;font-size:11pt;">&#32;per diluted share, compared with net income for the first quarter of 2014 of </font><font style="font-family:inherit;font-size:11pt;">$2.1 million</font><font style="font-family:inherit;font-size:11pt;">, or </font><font style="font-family:inherit;font-size:11pt;">$0.10</font><font style="font-family:inherit;font-size:11pt;">&#32;per diluted share.  Adjusted net income from continuing operations for the first quarter of 2015 was </font><font style="font-family:inherit;font-size:11pt;">$6.9 million</font><font style="font-family:inherit;font-size:11pt;">, or </font><font style="font-family:inherit;font-size:11pt;">$0.33</font><font style="font-family:inherit;font-size:11pt;">&#32;per diluted share, compared with adjusted net income from continuing operations for the first quarter of 2014 of </font><font style="font-family:inherit;font-size:11pt;">$7.3 million</font><font style="font-family:inherit;font-size:11pt;">, or </font><font style="font-family:inherit;font-size:11pt;">$0.35</font><font style="font-family:inherit;font-size:11pt;">&#32;per diluted share. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">As of March 31, 2015, Ligand had cash, cash equivalents, short-term investments and restricted investments of $177.8 million. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Full-Year and Second Quarter 2015 Financial Forecast </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand will provide a summary of the accounting impact of the recently-completed initial public offering of Viking Therapeutics by June 30, 2015 and will also update its 2015 financial forecast at that time. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Currently, the Company affirms expectations for full-year 2015 total revenues to be between $81.0 million and $83.0 million, and adjusted earnings per diluted share to be between $2.14 and $2.18. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">For the second quarter of 2015, Ligand expects total revenues to be between $17.0 million and $17.5 million, and adjusted earnings per diluted share to be between $0.37 and $0.40. Adjusted earnings per diluted share guidance excludes changes in contingent liabilities, mark-to-market adjustment for amounts owed to licensors, non-cash stock-based compensation expense and non-cash debt related costs.</font></div><div style="line-height:120%;padding-bottom:6px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">First Quarter and Recent Business Highlights</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Partnered Program Progress</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Promacta/Revolade</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Novartis completed the acquisition of Promacta and related assets from GSK on March 1, 2015.  Compared with GSK, Novartis has significantly larger oncology R&amp;D and commercial capabilities.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A submission was made to the EMA, seeking an additional indication for the treatment of pediatric patients with chronic immune thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids or immunoglobulins. The submission was based on the results from the Phase 3 PETIT2 study and the Phase 2 PETIT study in pediatric chronic ITP. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Kyprolis</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Interim analysis showed the Phase 3 ENDEAVOR clinical trial evaluating Kyprolis (carfilzomib) versus Velcade (bortezomib), met the primary endpoint of progression-free survival (PFS).   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Patients with relapsed multiple myeloma treated with Kyprolis lived twice as long without their disease worsening, 18.7 months for Kyprolis versus 9.4 months for Velcade.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Kyprolis demonstrated superiority over Velcade for overall response rate and lower neuropathy events.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The FDA accepted the sNDA of Kyprolis&#160;for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The FDA granted Kyprolis priority review with a PDUFA date of&#160;July 26, 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The EMA accepted the MAA of Kyprolis for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The MAA was granted accelerated assessment by the EMA.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Additional Pipeline and Partner Developments</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Spectrum Pharmaceuticals announced that its NDA for Captisol-Enabled Melphalan was accepted by the FDA and assigned a PDUFA date of October 23, 2015. Spectrum  is now referring to CE-Melphalan as EVOMELA&#8482;.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Melinta Therapeutics announced positive top-line results from the first of two Phase 3 PROCEED studies to evaluate delafloxacin, against vancomycin + aztreonam for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). </font></div></td></tr></table><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><a name="s0C0C47A3C9E650F991866C0E8F35B104"></a><br><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Delafloxacin met the study&#8217;s primary endpoint of a reduction in the measurement of lesion erythema at the primary infection site at 48-to-72 hours post-treatment, the endpoint required by the FDA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Delafloxacin was comparable to vancomycin in the study&#8217;s secondary endpoints, including investigator assessment of signs and symptoms of infection at the follow-up visit, a metric required by the EMA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SAGE Therapeutics announced completion of treatment for the first patient enrolled in its Phase 3 open-label expanded access protocol. Study 302 is designed to evaluate the safety of SAGE-547 in patients with SRSE.   In conjunction with this announcement, Ligand earned a $500,000 milestone payment from SAGE.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Retrophin announced the FDA granted orphan drug designation to sparsentan (RE-021) for the treatment of Focal Segmental Glomerulosclerosis (FSGS). Orphan designation will provide sparsentan with seven years of market exclusivity for FSGS upon approval. Prior to FDA approval, orphan designation provides incentives for sponsors including tax credits for clinical research expenses, the opportunity to obtain government grant funding to support clinical research, and an exemption from FDA user fees.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">TG Therapeutics announced the first presentation of preclinical data demonstrating single agent and combination activity with two of the Company's IRAK4 inhibitor compounds under development. The data demonstrated that:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Both IRAK4 inhibitors not only inhibited cell proliferation but also induced apoptosis as single agents in various B-cell lymphoma cell lines, potentially elucidating the mechanism of action of and clinical rationale for IRAK4 inhibition.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In addition, both compounds demonstrated marked synergy when combined with the novel targeted kinase inhibitors TGR-1202, the Company's proprietary PI3K delta inhibitor, and with the BTK inhibitor, ibrutinib.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Viking Therapeutics closed its initial public offering on May 5, 2015. In connection with the offering, Ligand received an equity milestone payment of 3.4 million shares.  Ligand invested an additional $9.0 million in the offering. Combining the value of the equity milestone and additional direct investment, Ligand owned 49.8% of Viking&#8217;s outstanding common stock at closing. Key programs licensed to Viking include:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">VK5211 (SARM) - Phase 2 program for hip fracture.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">VK2809 and VK0214 (TR&#946;) - Phase 2 program for dyslipidemia and nonalcoholic steatohepatitis (NASH). VK2809 is also in a preclinical program for adrenoleukodystrophy (ALD).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">VK0612 (FBPase) - Phase 2 program for type 2 diabetes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">EPOR - Preclinical program for anemia.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">DGAT-1 - Preclinical program for obesity and dyslipidemia.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Recent Acquisition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand acquired financial rights to potential future milestones and royalties for more than 15 development programs from Selexis SA for $4 million in cash. The acquired programs include a mix of novel biologics and biosimilars. The programs are in various stages of development ranging from preclinical through Phase 3. Each acquired program is fully funded by a development partner. The acquisition expands Ligand&#8217;s portfolio to more than 120 fully-funded assets and increases the number of partners to more than 70. Ligand previously acquired a portfolio of biologic development programs from Selexis in April, 2013.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">New Licensing Deal</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand and Sermonix Pharmaceuticals announced the signing of a license agreement for the development and commercialization of oral lasofoxifene in the U.S. and additional territories. Under the terms of the agreement, Ligand has received an undisclosed initial payment, and is entitled to receive up to $45 million in potential regulatory and commercial milestone payments and tiered royalties of 6% to 10% on future net sales. Lasofoxifene is an estrogen partial agonist for the treatment of osteoporosis and other diseases.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><a name="s0C0C47A3C9E650F991866C0E8F35B104"></a><br><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Internal Program Progress</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand announced that enrollment was completed for the Phase 1b Multiple-Ascending Dose trial of the Glucagon receptor antagonist LGD-6972. Data from the trial will be presented in a poster presentation at American Diabetes Association 75</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;Scientific Sessions in Boston on June 7</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;at 12:00 p.m. ET. The Company will also host an investor presentation that evening beginning at 7:00 p.m. ET in Boston.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Adjusted Financial Measures</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The adjusted financial measures discussed above and in the tables below for the three months ended March 31, 2015 and 2014 exclude changes in contingent liabilities, mark-to-market adjustment for amounts owed to licensors, non-cash stock-based compensation expense, and non-cash debt related costs.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Management has presented net income, net income per share, income from continuing operations and income from continuing operations per share in accordance with GAAP and on an adjusted basis.  Ligand believes that the presentation of adjusted financial measures provides useful supplementary information to investors and reflects amounts that are more closely aligned with the cash profits for the period as the items that are excluded from adjusted net income are all non-cash items.  Ligand uses these adjusted financial measures in connection with its own budgeting and financial planning.  These adjusted financial measures are in addition to, and not a substitute for, or superior to, measures of financial performance prepared in conformity with GAAP.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Conference Call</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand management will host a conference call today beginning at 9:00 a.m. Eastern time (6:00 a.m. Pacific time) to discuss this announcement and answer questions.&#160; To participate via telephone, please dial (877) 407-4019 from the U.S. or (201) 689-8337 from outside the U.S., using the passcode &#8220;Ligand.&#8221; A replay of the call will be available until August 11, 2015 at 9:00 a.m. Eastern time by dialing (877) 660-6853 from the U.S. or (201) 612-7415 from outside the U.S., using passcode 13608254. Individual investors can access the webcast at www.ligand.com.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">About Ligand Pharmaceuticals </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ligand is a biopharmaceutical company with a business model focused on developing or acquiring royalty generating assets and coupling them with a lean corporate cost structure. Ligand&#8217;s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies seek to address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer&#8217;s disease, dyslipidemia, anemia, asthma and osteoporosis.  Ligand&#8217;s Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.  Ligand has established multiple alliances with the world's leading pharmaceutical companies including Novartis, Amgen Inc., Merck, Pfizer, Baxter International and Eli Lilly &amp; Co.  Please visit www.captisol.com for more information on Captisol and www.ligand.com for more information on Ligand.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Follow Ligand on Twitter @Ligand_LGND.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><a name="s0C0C47A3C9E650F991866C0E8F35B104"></a><br><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release.  Words such as &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; and &#8220;will,&#8221; and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding: Ligand&#8217;s future growth, Ligand's outlook for Captisol orders, expected value creation for shareholders and guidance regarding second-quarter and full-year 2015 financial results.  Actual events or results may differ from Ligand's expectations. For example, Ligand may not receive expected revenue from material sales of Captisol, expected royalties on partnered products and research and development milestone payments.  Ligand and its partners may not be able to timely or successfully advance any product(s) in its internal or partnered pipeline.  In addition, there can be no assurance that Ligand will achieve its guidance for 2015 or beyond, that Ligand's 2015 revenues will be at the levels or be broken down as currently anticipated, that Ligand will be able to create future revenues and cash flows by developing innovative therapeutics, that results of any clinical study will be timely, favorable or confirmed by later studies, that products under development by Ligand or its partners will receive regulatory approval, that there will be a market for the product(s) if successfully developed and approved, or that Ligand's partners will not terminate any of its agreements or development or commercialization of any of its products.  Further, Ligand may not generate expected revenues under its existing license agreements and may experience significant costs as the result of potential delays under its supply agreements.  Also, Ligand and its partners may experience delays in the commencement, enrollment, completion or analysis of clinical testing for its product candidates, or significant issues regarding the adequacy of its clinical trial designs or the execution of its clinical trials, which could result in increased costs and delays, or limit Ligand's ability to obtain regulatory approval.  Further, unexpected adverse side effects or inadequate therapeutic efficacy of Ligand's product(s) could delay or prevent regulatory approval or commercialization.  In addition, Ligand may not be able to successfully implement its strategic growth plan and continue the development of its proprietary programs.  The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand's stock price.  Additional information concerning these and other risk factors affecting Ligand can be found in prior press releases available at  www.ligand.com as well as in Ligand's public periodic filings with the Securities and Exchange Commission available at www.sec.gov.  Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.  This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. </font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[Tables Follow]</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><a name="s0C0C47A3C9E650F991866C0E8F35B104"></a><br><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">LIGAND PHARMACEUTICALS, INCORPORATED</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(Unaudited, in thousands, except per-share data)</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="68%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #333333;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #333333;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #333333;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Royalties</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,287</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,850</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Material sales</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,729</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,715</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Collaborative research and development and other revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #333333;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">586</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #333333;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #333333;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #333333;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,602</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15,958</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating costs and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,074</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,451</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,962</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,131</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,994</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,072</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-continuing expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">223</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">204</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;Total operating costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,253</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,858</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Gain from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #333333;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,349</font></div></td><td style="vertical-align:bottom;border-top:1px solid #333333;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #333333;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,100</font></div></td><td style="vertical-align:bottom;border-top:1px solid #333333;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,420</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,002</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Increase in contingent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,948</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(53</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net income (loss) including noncontrolling interests</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(89</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,097</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Less: Net loss attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(843</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net income </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">754</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,097</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Per-share net income:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Basic and diluted net income </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.04</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Weighted average number of common shares-basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">19,611,881</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">20,600,683</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Weighted average number of common shares-diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">20,630,788</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">21,208,023</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><a name="s0C0C47A3C9E650F991866C0E8F35B104"></a><br><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">LIGAND PHARMACEUTICALS, INCORPORATED</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(Unaudited, in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="49%"></td><td width="1%"></td><td width="20%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="20%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #333333;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #333333;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Cash, cash equivalents and short-term investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">177,225</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167,336</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,423</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,634</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,821</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">269</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,156</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,597</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Current portion of co-promote termination asset</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">322</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,713</font></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185,158</font></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">600</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,261</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">440</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">486</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Goodwill and other identifiable intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,367</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,961</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Commercial license rights</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,568</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,568</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,535</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,595</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #333333;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #333333;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #333333;padding-top:2px;padding-bottom:2px;border-top:2px solid #333333;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,223</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #333333;border-top:2px solid #333333;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #333333;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #333333;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #333333;padding-top:2px;padding-bottom:2px;border-top:2px solid #333333;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">258,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #333333;border-top:2px solid #333333;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities and Stockholders' Equity</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,721</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,123</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Current portion of co-promote termination liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">322</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Current portion of note payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">348</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,157</font></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,779</font></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Long-term portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,085</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,085</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Long-term debt, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198,219</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195,908</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,367</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,849</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230,828</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,621</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Total Ligand Pharmaceuticals Inc. stockholders' equity </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,148</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,318</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,753</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,910</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities and stockholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #333333;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #333333;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #333333;padding-top:2px;padding-bottom:2px;border-top:2px solid #333333;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,223</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #333333;border-top:2px solid #333333;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #333333;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #333333;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #333333;padding-top:2px;padding-bottom:2px;border-top:2px solid #333333;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">258,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #333333;border-top:2px solid #333333;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><a name="s0C0C47A3C9E650F991866C0E8F35B104"></a><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ADJUSTED FINANCIAL MEASURES</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(Unaudited, in thousands, except share data)</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="73%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #333333;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #333333;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #333333;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">754</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,097</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Increase in contingent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,948</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Mark-to-market adjustment for investments owed to licensors</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">699</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,233</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-cash stock-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,914</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,067</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-cash debt related costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,509</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Adjusted net income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,879</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,345</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Diluted per-share net income:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net income </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.04</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Increase in contingent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.09</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Mark-to-market adjustment for investments owed to licensors</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.06</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-cash debt related costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Adjusted net income </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.33</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.35</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Weighted average number of common shares-diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">20,630,788</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">21,208,023</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">###</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ligandlogoa03a01a01a01.jpg
<TEXT>
begin 644 ligandlogoa03a01a01a01.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X0!817AI9@``34T`*@````@`!`$Q``(`
M```1````/E$0``$````!`0```%$1``0````!```N(U$2``0````!```N(P``
M``!!9&]B92!);6%G95)E861Y``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`(+!<8#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`KB-?\`B-;Z;=SV5C:-<3Q,T;R2':BN..!U8`Y!Z=.#SFNWKYQH
M`ZR[^(WB"YV>5);VNW.?)A!W?7?N_3'6J_\`PGOB7_H)?^0(_P#XFN;HI@=)
M_P`)[XE_Z"7_`)`C_P#B:DM_B#XCAG622[CG49S')"H4\=]H!_6N7HH`],TG
MXGQ2/'%JMGY6>&G@)*@Y[H>0`.N"3QTYKT".1)HDEB=7C=0RLIR&!Z$'N*^<
MZ]M\#2/+X,TYI'9V"NH+')P'8`?0``?A2`Z&BBB@`HHHH`****`(+R\M["TE
MNKJ58H(EW.[=`/ZGV[UY;KGQ'U"^WPZ:GV*W.1YG65AR.O1>".G((^]5+QMX
MDEUK5I+>&;.GVSE8E4C#L."^03GG.#Z>F3G8\*^$[*'1)/$&M0M-&L;3Q6V"
M,(O.X@XW$XX!XP><YX`.7M=$U_Q#*;F*UNKIG7=]HE;`<#Y?OL<$CIC/;VJS
M)X&\211/(VF,512Q"RHQP/0!LD^PKN/^%GZ+_P`^NH?]^T_^+H_X6?HO_/KJ
M'_?M/_BZ8'`V.NZ[X;N5@2:XA\K@VEP#M`)#8V'IGU&#SUYKTGPKXUM_$#?9
M;B-;:_"Y"!LK*`.2OH>OR\\=SSB21=`\?:6`LC,8F!RORRP$C..0>#T[@XXY
M&1Y3JVFW?A[69+:0R1R0ONAE'REES\KK@\=/7@\=10![Y17/>#?$!U_1%DG=
M3>0-Y<X``R>S8!Z$?3D-@<44@.AHK-U37]*T;:-0O8X6;&$Y9B#GG:,G'!YQ
MBN>D^)NAI*Z+#?2*K$!UC7##U&6!Q]0*`.SHKSJ3XJH)7$6CLT88[6:XVDCL
M2-IP?;)IO_"UO^H+_P"37_V%`'H]%<':_%+3GB)N]/NHI-W"Q%9!CUR2O/7C
M%;-AXZ\/W_EK]M^SROGY+A2FW&>K?='3U_7B@#HZ***`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"OG&OHZOG&@`HHHI@%%%
M%`!7M?@+_D2]/_[:?^C&KQ2O:_`7_(EZ?_VT_P#1C4`='1112`****`"L?Q7
M?OIOA?4+J+=Y@CV*5;:5+$*&!]1NS^%;%<YX]_Y$O4/^V?\`Z,6@#RCPYIHU
M;Q%8V3A3')(#(&)`*+\S#(YR0"*]H\0_\BUJO_7G-_Z`:\G\!?\`(Z:?_P!M
M/_1;5ZQXA_Y%K5?^O.;_`-`-`'CWA&PMM4\3V=G>1>;;R;]Z;BN<(Q'((/4"
MNQ\8>"M(L="EO[$?8WM^6!9W60$@;><D')&#TYY]1YY8?;?ML?\`9WVC[7SY
M?V?=OZ'.-O/3/X59U;^V_P!S_;']H?Q>5]LW^V=N[\,X]J8&IX`D=/&=DJ.R
MJZR*X!P&&QC@^HR`?P%==\3-)6XTF'4XX_WMLX21A@?NV]>YPV,>FXU2^&+Z
M47G189%U548M(S$J\1*]!T&"!UYYZ]ATGCW_`)$O4/\`MG_Z,6D!YQX-\10>
M'=3GFNA</;RP[#'#@Y;(()!('`W?G[T5S=%,">\O+B_NY;JZE:6>5MSNW4G^
M@]NU0444`%%%%`!1110!ZI\,=2EN=)NM/D&5M'!C;C[KY.W&.Q!.?]KVKNJ\
MX^%/_,7_`.V/_L]>CT@"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"OG&OHZOG&@`HHHI@%%%%`!7M?@+_`)$O3_\`MI_Z,:O%
M*]K\!?\`(EZ?_P!M/_1C4`='1112`****`"J6L6/]IZ->606,M-"R)Y@^4-C
MY2?H<'\*NT4`?/5O-/I>IQ3>7MN+68/Y<BD893G##@]1S7M6HWT&I^"KZ]MV
MS%-82NO(R/D/!QW!X/N*X_Q]X1E6>;6[!-\;?-<Q*H!0XY<8Z@]3W!R>A..;
M\,^)I="G>&9/M&FW'%Q;,`001@L`>,X[=".#V(8$O@+_`)'33_\`MI_Z+:O1
M_'5A]O\`"5WMBWRV^)T^;&W:?F/7GY2W']<4S1=1\(W30W&GIIMO<E@J*8DB
ME#$?=`X)/..,@\C)K=OKBRM[9O[0FMXK>3]V?M#*JMD'Y>>#D9XI`>-^![P6
M?B^Q9Y6CCE9HFQG#%E(4''4;MOZ'M72?$_6$=K;1X]K,C>?,>I4X(4=>#@DD
M$=UIOB3Q'X9M8);;1]*T^>[/R^?]D3RX^2"1D?,>./X><Y/0\9INFW_B#5!;
MVX::XE8N\CDD`9Y=CZ<]?YDTP.J^&^B0:A<WMY>6T<UO&@B1)H0ZLQ.203QD
M`#_OK\RO1=%TFWT32X;&W5<(HWN%P9'QRQZ\GZ\<#H**0'@%%%%,`HHHH`**
M**`/1_A3_P`Q?_MC_P"SUZ/7G'PI_P"8O_VQ_P#9Z]'I`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%?.-?1U?.-`!1113`**
M**`"O:_`7_(EZ?\`]M/_`$8U>*5[7X"_Y$O3_P#MI_Z,:@#HZ***0!1110`4
M444`%<9X@^'EAJ3/<:<RV-QM_P!6J#RF(![#[I/'(].A)KLZ*`/&[KX=^(;>
M4)%;PW*E<[XIE`!]/FVG/X=ZA_X0+Q+_`-`W_P`CQ_\`Q5>U44`>5Z3\,]0N
M'CDU.>.UBZM'&=\G7I_=&1GG)QQQ7HNDZ+8:):+;V,"H-H#R$#?(1GECW/)^
MF>,"K]%`!1110!\XT444P"BBB@`HHHH`]'^%/_,7_P"V/_L]>CUYQ\*?^8O_
M`-L?_9Z]'I`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`52O]7T_3%)O+N*
M(@!MA.6()QD*.3^5<;XM\6S?:)--TV1XA$^V:9258L#]U3U`!ZGO].O$5Y.)
MS14Y.%-7\^A[&%RJ52*G4=D^G4]5F\;:%%$SI<O,PZ(D3`G_`+Z`'ZU4_P"%
MA:3_`,^][_WPG_Q5>:T5PO-<0]K+Y'='*<.M[OYGJL/C;0I8E=[EX6/5'B8D
M?]\@C]:U+#5]/U-0;.[BE)!;8#A@`<9*GD?E7BU%:0S>JG[T4_P(GD])KW9-
M?B>[45P'A+Q;-]HCTW4I'E$K[89F)9@Q/W6/4@GH>WTZ=_7LX?$0KPYHGB8G
M#3P\^284445N<X4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!7SC7T=7SC0`4444P"BBB@`KVOP%_P`B7I__`&T_]&-7BE>U^`O^
M1+T__MI_Z,:@#HZ***0!1110`4444`%%%%`!1110`4444`%%%%`'SC1113`*
M***`"BBB@#T?X4_\Q?\`[8_^SUZ/7G'PI_YB_P#VQ_\`9Z]'I`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!6=KM^=-T.\NU+!TCPA4`X8\*<'W(K1KE_'TTD7AU
M41L++.J.,=1@MC\U'Y5AB9N%&4EV-\-!5*T8OJSS&BBBOD#[,****`"BBB@`
MKVO2[S^T-*M;LE"TL2LVP\!L<C\#D?A7BE>L^#?^13LO^VG_`*&U>ME$FJLH
M^7]?F>/G,4Z49=G^?_#&[1117T!\Z%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`5\XU]'5\XT`%%%%,`HHHH`*]K\!?\B7I_P#V
MT_\`1C5XI7M?@+_D2]/_`.VG_HQJ`.CHHHI`%%%%`!1110`4444`%%%%`!11
M10`4444`?.-%%%,`HHHH`****`/1_A3_`,Q?_MC_`.SUZ/7G'PI_YB__`&Q_
M]GKT>D`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%<G\0O\`D`0?]?2_^@O765S'
MCRW>?PV9%*@03)(V>XY7C\6%<N-3>'G;L=6":6(A?N>84445\F?8!1110`44
M44`%>G>`89(O#K.ZX66=G0YZC`7/YJ?RKS&O6O!Z/'X5L5=64D.V&&."[$'\
M00:]/*8WKM]E_D>5F\K4$N[_`,S<HHHKZ,^:"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`*^<:^CJ^<:`"BBBF`4444`%>U^`O^
M1+T__MI_Z,:O%*]K\!?\B7I__;3_`-&-0!T=%%%(`HHHH`****`"BBB@`HHH
MH`****`"BBB@#YQHHHI@%%%%`!1110!Z/\*?^8O_`-L?_9Z]'KSCX4_\Q?\`
M[8_^SUZ/2`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBLW_A(=%_Z#&G_^!*?XT`:5%8%QXV\.6T[0R:I&67&3&C2+TSPR
M@@_G4?\`PGOAK_H)?^0)/_B:`.CHKGH_'/AN65(UU-0SL%!:)U&3ZDK@#W-7
M_P#A(=%_Z#&G_P#@2G^-`&E13(9HKB)989$DC;HZ,"#^(I]`!1110`4444`%
M4M7L!J>DW5F0I,L9";B0`W52<>A`-7:*4HJ2<7LRHR<9*2W1X6Z/%(T<BLCJ
M2K*PP01U!%-KT;Q/X-_M"5KW30B7#9,L1.!(?4>C'\CUXYSP5YIUYI\FR\MI
M8220-ZD!L=<'H?PKY/$86I0DU):=SZ[#8NG7BG%Z]BM1117,=0445=L-(U#4
MV`L[264$E=X&%!`S@L>!^=.,7)VBKLF4HQ5Y.R*T$,ES<1P1+NED<(BYQDDX
M`YKVVUMTL[."VC+%(8UC4MU(`P,_E7/^&?"D>BYN;HI->G(#+RL8_P!G/<]S
M^'KGI:^CR["2HQ<I[L^:S+%QKR48;+\0HHHKTCS`HHHH`****`"BBB@`HHHH
M`**J76JZ=8RB*[O[6WD*[@LLRH2/7!/3@U4N/%&A6T#32:M9E5QD1RB1NN.%
M7)/Y4`:U%<Y_PGOAK_H)?^0)/_B:/^$]\-?]!+_R!)_\30!T=%85KXR\/7DI
MCBU2%6"[LRAHACZL`,\]*M_\)#HO_08T_P#\"4_QH`TJ*;'(DT22Q.KQNH96
M4Y#`]"#W%.H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHK-_X2'1?^@QI_\`X$I_C0!I45SG_">^
M&O\`H)?^0)/_`(FC_A/?#7_02_\`($G_`,30!T=%9<?B30Y8DD75[$*ZA@&G
M53@^H)R#[&KMK>6M]$9;2YAN(PVTM%('`/ID=^10!/1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`454NM5TZQ
ME$5W?VMO(5W!99E0D>N">G!JE=>*]`LXA)+JUJREMN(G\TY^BY...M`&Q17.
M?\)[X:_Z"7_D"3_XFG1^.?#<LJ1KJ:AG8*"T3J,GU)7`'N:`.AHK-_X2'1?^
M@QI__@2G^-:5`!1110`4444`%%%%`!7SC7T=7SC0`4444P"BBB@`KVOP%_R)
M>G_]M/\`T8U>*5[7X"_Y$O3_`/MI_P"C&H`Z.BBBD`4444`%%%%`!1110`44
M44`%%%%`!1110!\XT444P"BBB@`HHHH`]'^%/_,7_P"V/_L]>CUYQ\*?^8O_
M`-L?_9Z]'I`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110!RNO>/=,T:62VB#7EVC;6CC.U4(QD,WKR>@/(P<5R<GQ0U<RN8K
M.Q6,L=JLKL0.P)W#)]\"N+N+B6[N9;B9MTLKEW;`&6)R3@>]1TP.HN/B#XCF
MG:2.[C@4XQ''"I4<=MP)_6H_^$]\2_\`02_\@1__`!-<W10!VO\`PL_6_P#G
MUT__`+]O_P#%ULZ;\4+>66./4K%H%*@--$^\;N,G;C(7J>I/UKS&B@#Z,CD2
M:))8G5XW4,K*<A@>A![BG5SG@+_D2]/_`.VG_HQJZ.D`4444`%%%%`!1110`
M4444`%%%9NLZ[I^@VPFOYMF_(CC49:0@9P!_4X'(R1F@#2K-U37]*T;:-0O8
MX6;&$Y9B#GG:,G'!YQBO+]:^(.KZIF.U;[!;G^&%OG/3J_!Z@],<'!S7)T`>
MCW_Q3_UB:=IOIY<MP_TSE%_$?>]_:N7OO&OB"_W!]1DA0OO"VX$>WKQD?,1S
MW)K`HI@27%Q/=SM-<3232MC=)(Q9C@8Y)]JCHHH`****`"BBB@`K;M/%_B"R
MW^5JMPV_&?.(EZ>F_..O:L2B@#T73?BDX8+JFGJ5+',EJ<$#'`VL>3GON'7V
MY[/2?$ND:RD?V2\C\U^/(D.V0'&2-IZX'<9'!YKP>B@#Z.HKQW1?B#J^EXCN
MF^WVX_AF;YQUZ/R>I'7/`P,5Z=H_B'3-=B#6-RK2!<M"WRR+TSE?09`R,C/>
MD!J4444`%%%%`%)]'TR61I)-.M'=B69F@4DD]23BF_V)I/\`T"[+_P`!T_PJ
M_14>SAV1?M9_S,J0Z5I]M*LL%A:Q2KT=(54CMU`JW115**CHD3*3EJV%%%%,
M04444`%%%9NJ:_I6C;1J%['"S8PG+,0<\[1DXX/.,4`:5%>8ZM\3[B1FCTFU
M6*,J1YMP-SY('(4'`(.>N[/'TKC]2US4]78F_O9IE+!MA;"`@8R%'`./0=S0
M!Z[J7C?0--4YO5N9-H81VO[PD$XZCY0>^"1_*N9O_BG_`*Q-.TWT\N6X?Z9R
MB_B/O>_M7G%%,#IKSQ]XANVEVWBV\<B[?+AC4!1C'!.6![YS]*PKO4;V_P!G
MVR\N+C9G9YTK/MSUQD\=!5:B@`HHHH`****`"BBB@`K6M_%&NVTZS1ZM>%ES
M@22F1>F.5;(/Y5DT4`=K8?$S5[?RUO(+>[1<[VQY;MUQR/E&./X>@_&NMTSX
MAZ)?;4N'DLI3M&)ERI8]<,.P/=L?SQX[10!]%6]Q!=P+-;S1S1-G;)&P93@X
MX(]ZDKY^TW5]0T><S:?=R0,?O!3E6X(Y4\'J>HXKT70?B3;WDL=MJT*VTKMM
M$\9_=9.?O`\J.@SD^IP*0'>44V.1)HDEB=7C=0RLIR&!Z$'N*=0`4444`%%%
M%`!1110`4444`<AX@^(%AHUV]G;P->W$;8DVN%1#SD;L'+#CC'?KD8KE?^%G
MZW_SZZ?_`-^W_P#BZXZXN);NYEN)FW2RN7=L`98G).![U'3`Z3_A/?$O_02_
M\@1__$U);_$'Q'#.LDEW'.HSF.2%0IX[[0#^M<O10!W5O\4=46=3<6-G)%SN
M6/<C'CL23CGVKM_#GBJP\1Q,(-T-S&H,D$A&0..5/=<\9_,#(KPZNH^'UQ+#
MXQM8XVPLR2)(,#E=I;'YJ#^%`'LU%%%(`HHHH`*;)(D,3RRNJ1HI9F8X"@=2
M3V%<=X@^(=AIK/;Z<JWUQM_UBN/*4D'N/O$<<#UZ@BO.-8\0ZGKLI:^N6:,-
ME85^6->N,+ZC)&3DX[T`>DZM\1](L'DBM$DOI5XS'\L><X(W'VYR`0>.:XJ^
M^('B"]W!+B.U1DV%;>,#UYR<L#SV(Z5R]%,">ZO+J^E$MW<S7$@7:&ED+D#T
MR>W)J"BB@`HHHH`****`-:Q\3ZWIVT6VIW`54V*CMYBJO&`%;('3L*ZC3/B?
M=Q;8]3LXYU^4&6$[&Q_$Q!R">^!M'].!HH`]ZT?Q#IFNQ!K&Y5I`N6A;Y9%Z
M9ROH,@9&1GO6I7SG'(\,J2Q.R2(P964X*D="#V-=MX?^(U[9,D&K!KNV"X$B
M@>:O`QSD!AQWYYSD]*0'JU%06=Y;W]I%=6LJRP2KN1UZ$?T/MVJ>@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`***Y/Q%X\T_1_.M;4_:K],KM`^2-N
M/O'OU/`SR"#B@#JI)$AB>65U2-%+,S'`4#J2>PKE]6^(&BZ8S10R->S!3@6^
M"@.`0"_3!SU&<8->7ZQXAU/792U]<LT8;*PK\L:]<87U&2,G)QWK+H`[/4OB
M5K%TQ%DD-E'N!!"^8^,<@EN",\_=';\>9OM8U+4]PO;ZXG4OOV/(2H;GD+T'
M4]!5*BF`4444`%%%%`!4]K>75C*9;2YFMY"NTM%(4)'ID=N!4%%`'6:9\0];
ML=J7#QWL0VC$RX8*.N&'<CNV?YY[;1?B#I&J8CNF^P7!_AF;Y#UZ/P.@'7')
MP,UX[10!]'45X9HOBO5]"PEK<;[<?\N\WS)WZ#JO))X(R>N:]4\/^+M-\0($
MC?R+L8!MY6&XG&3M_O#@^_'(%(#?HHHH`*^<:^CJ^<:`"BBBF`4444`%>U^`
MO^1+T_\`[:?^C&KQ2O:_`7_(EZ?_`-M/_1C4`='1112`****`"BBB@`HHHH`
M****`"BBB@`HHHH`^<:***8!1110`4444`>C_"G_`)B__;'_`-GKT>O./A3_
M`,Q?_MC_`.SUZ/2`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@#YQHHHI@%%%%`!1110![7X"_Y$O3_^VG_HQJZ.N<\!?\B7
MI_\`VT_]&-71T@"BBB@`HHHH`****`"BBN!\;>-OL?F:5I4O^D\K/<*?]5ZJ
MI_O>I[?7H`6?%?CR#2_/T_33YM^ORM+@%(CW^K#TZ`GGH17EMY>7%_=RW5U*
MTL\K;G=NI/\`0>W:H**8!1110`4444`%%%%`!1110`4444`%%%%`!1110`5/
M9WEQ87<5U:RM%/$VY'7J#_4>W>H**`/6?"GCR#5/(T_4CY5^WRK+@!)3V^C'
MTZ$CCJ!7:U\XUZAX)\;?;/+TK59?])X6"X8_ZWT5C_>]#W^O5`=]1110`444
M4`%%%%`!1110`56OM0M-,MFN+VXC@B'\3G&3@G`'<X!X'-0ZUJ]OHFES7UPR
MX13L0M@R/CA1UY/TXY/05XEK.NZAKUR)K^;?LR(XU&%C!.<`?U.3P,DXH`ZC
MQ!\1[F^0V^D))9Q'(:9L>8P(Q@==O)/()/3D5P\DCS2O+*[/([%F9CDL3U)/
M<TVBF`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!TWACQE
M>Z!+%!*S3Z;N.Z#C*YZE#V/?'0Y/0G->PV=Y;W]I%=6LJRP2KN1UZ$?T/MVK
MYXKH?"OBJX\.7>UMTMA*W[Z$'D'^\OHW\^A[$`'MM%1V]Q%=VT5Q`VZ*5`Z-
M@C*D9!P?:I*0!1110`4444`%%%%`'SC1113`****`"ND\!?\CII__;3_`-%M
M7-UTG@+_`)'33_\`MI_Z+:@#VJBBLGQ!X@M/#NGFXN#OE;(AA!PTC?T`[GM]
M2`4!;U+4[+2+0W5_<+#"&"[B"22>P`Y)^GH:\F\2^.+_`%MGM[8M:V&X@(A(
M>12,?.0>1UX''/.<`UCZSKNH:]<B:_FW[,B.-1A8P3G`']3D\#).*S:8!111
M0`4444`%%%%`!1110`4444`%%%%`!1110!K>'_$%WX=U`7%N=\;8$T).%D7^
MA'8]OH2#[%X?\06GB+3Q<6YV2K@30DY:-OZ@]CW^H('@]:6A:S/H.K0W\(W[
M,J\98@2*>H./S'7D`X.*`/?**I:3JUIK6GQWME)OB;@@\,C=U8=B/_K]#5VD
M`4444`%%%%`!1110`4444`%%%%`!39)$AB>65U2-%+,S'`4#J2>PJ*\O+>PM
M);JZE6*")=SNW0#^I]N]>,^*O%5QXCN]J[HK")OW,)/)/]YO5OY=!W)`-3Q7
MX\GU3S]/TT^58-\K2X(>4=_HI].I`YZD5Q5%%,`HHHH`****`"BBB@`HHHH`
M****`"BBB@`IT<CPRI+$[)(C!E93@J1T(/8TVB@#T?PI\0?]1IVLM_LK>LWY
M!_U^;/IGN:]%CD2:))8G5XW4,K*<A@>A![BOG.NO\&^,GT.5;*]9GTUVX/4P
M$]QZKZC\1SD%`>OU\XU]#V=Y;W]I%=6LJRP2KN1UZ$?T/MVKYXH`****8!11
M10`5[7X"_P"1+T__`+:?^C&KQ2O:_`7_`")>G_\`;3_T8U`'1T444@"BBB@`
MHHHH`****`"BBB@`HHHH`****`/G&BBBF`4444`%%%%`'H_PI_YB_P#VQ_\`
M9Z]'KSCX4_\`,7_[8_\`L]>CT@"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`^<:***8!1110`4444`>U^`O^1+T_P#[:?\`
MHQJZ.N<\!?\`(EZ?_P!M/_1C5T=(`HHHH`****`"BBH+R\M["TENKJ58H(EW
M.[=`/ZGV[T`<]XT\4?\`"/Z>L5J\9U"?A%/)C7G+X^O`SW]<$5XS6AK6KW&M
MZI-?7#-EV.Q"V1&F>%'3@?3GD]36?3`****`"BBB@`HHKNO#_P`.+F^07&KO
M)9Q'!6%0/,8$9R>NWDC@@GKP*`.'CC>:5(HD9Y'8*JJ,EB>@`[FMNU\&^(;R
M(R1:7,JAMN)2L1S]&(..>M>R:;I&GZ/`8=/M(X%/WBHRS<D\L>3U/4\5=I`>
M3?\`"L-;_P"?K3_^_C__`!%'_"L-;_Y^M/\`^_C_`/Q%>LT4`>17'PTUV&!I
M(WLYV&,1QRD,>>VX`?K63=^$/$%EL\W2KAM^<>2!+T]=F<=>]>YT4`?.-%>]
M:QX>TS78BM];*T@7"S+\LB]<8;T&2<'(SVKSCQ!\/+_35>XTYFOK?=_JU0^:
MH)/8?>`XY'KT`%,#C****`"BBB@`HHHH`]F\%^*/^$@T]HKIXQJ$'#J.#(O&
M'Q]>#COZ9`KJ*\!T75[C1-4AOK=FRC#>@;`D3/*GKP?IQP>HKWJWN(KNVBN(
M&W12H'1L$94C(.#[4@)****`"BBB@`HHHH`\V^*=X#+IUDLK;E5Y9(^<8.`I
M/8GAQ[<^M>=5VOQ/_P"1EMO^O-?_`$-ZXJF`4444`%%%%`!13HXWFE2*)&>1
MV"JJC)8GH`.YKI--\!:_J*AS;+:1E20UTVPD@XQM`+`_4?TH`YFBO4K#X7V$
M,N^^OIKE0P*I&@B!`ZAN22#QT(KI+7PIH%G$8XM)M64MNS*GFG/U;)QQTH`\
M)K0CT+5YHDEBTJ^>-U#*RV[D,#T(..17OD<:0Q)%$BI&BA551@*!T`'84ZD!
MX'_PCVM_]`?4/_`9_P#"FR:%J\,3RRZ5?)&BEF9K=P%`ZDG'`KWZB@#YQHKZ
M*N+>"[@:&XACFB;&Z.10RG!SR#[UA:EX(T#4E.;);:3:%$EK^[(`.>@^4GMD
M@_RI@>)45WFK?#*]MU:72[E;I=QQ#(`C@9&`#G!.,Y)V]/?%</<6\]I.T-Q#
M)#*N-T<BE6&1GD'VH`CHHHH`****`"BBB@#T/X;>(&2<Z%.<H^Z2W8DDAL9*
M8Z`8!;MSGKFO2Z^=;>XEM+F*XA;;+$X=&P#A@<@X/O7OND:E%K&DVVH0C"S)
MDKS\K=&7)`S@@C/?%("[1110`4444`%%%%`'SC1113`****`"ND\!?\`(Z:?
M_P!M/_1;5S=:GAW54T37(-1DC:585?"*<%B48`9[#)'/\Z`/9/$'B"T\.Z>;
MBX.^5LB&$'#2-_0#N>WU(!\4U;5KO6M0DO;V3?(W``X5%[*H[`?_`%^IHU;5
MKO6M0DO;V3?(W``X5%[*H[`?_7ZFJ5`!1110`4444`%%6;'3[O4[E;>RMY)Y
M3_"@S@9`R3V&2.3Q77Z;\,M3N5#W]S#9J5/R@>:X.>A`(&,<Y!/;\`#AZ*]?
MM?AOH%O*7E%U<J5QLEEP`?7Y0IS^/>KG_"!>&O\`H&_^1Y/_`(J@#Q2BO:)/
M`'AMXG1;!HV92`ZSOE3ZC)(S]0:Q[OX663[/L>I7$.,[_.19,^F,;<=_6@#R
M^BM_5O!FMZ0DDLUKYUNG6:`[UQC))'W@!@Y)`%8%`!1110`4444`%%%%`'5>
M!_$IT35!;7$C?8+E@K`L`L;D@!^>@['D<<\X`KV2OG&O9/`6O/K.B&*YD:2[
MM&"2,QR74_=8G'7@CN?ER>M(#JJ***`"BBB@`HHHH`****`"BBN*^(7B/^SM
M/_LJW;%U=I^\RF0L)R#SZDC'?C/3@T`<SXY\6/JMW)IME,ITZ)AN:,Y$[#N3
M_=!Z#H<9YXQQE%%,`HHHH`****`"BBB@`HKJ-)\`ZWJ3QM-!]BMVY,D_#`9P
M<)][/4C.`<=:ZRQ^&&FP[6O;RXN6#YP@$:E>/E(Y/KR".M`'E=%>VQ^!O#<4
MJ2+IBED8,`TKL,CU!;!'L:MW'A?0KF!H9-)LPK8R8XA&W7/#+@C\Z`/!Z*]F
MN/A]X<F@:..TD@8XQ)',Q8<]MQ(_2L+4OA:A4MI>H,&"C$=T,@G/)W*.!CMM
M/3WX`/-J*U-8\/:GH4I6^MF6,MA9E^:-NN,-ZG!.#@X[5ET`%%%%`!1110!T
M/A7Q5<>'+O:VZ6PE;]]"#R#_`'E]&_GT/8CGJ**`"BBB@`HHHH`*]K\!?\B7
MI_\`VT_]&-7BE>U^`O\`D2]/_P"VG_HQJ`.CHHHI`%%%%`!1110`4444`%%%
M%`!1110`4444`?.-%%%,`HHHH`****`/1_A3_P`Q?_MC_P"SUZ/7G'PI_P"8
MO_VQ_P#9Z]'I`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110!\XT444P"BBB@`HHHH`]K\!?\B7I__;3_`-&-71USG@+_`)$O
M3_\`MI_Z,:NCI`%%%%`!1110`5Y[\3]6:."TTJ*3'FYFF49!*@X49Z$$[CCU
M4=*]"KP7Q'J0U;Q%?7J%3')(1&5!`*+\JG!YR0`:`,NBBBF`4444`%%%=U\.
M/#ZWUZVKW`S%:OMB4@$-)CJ?3:""..I'/%`&MX)\$_8_+U758O\`2>&@MV'^
MJ]&8?WO0=OKT[ZBBD`4444`%%%%`!1110`4444`<#XV\$_;/,U72HO\`2>6G
MMU'^M]64?WO4=_KU\OKZ.KR;XA>'/[.U#^U;=<6MV_[S+Y*S')/'H0,]^<].
M!0!Q5%%%,`HHHH`*]0^&>M>?93:/*?GM\RP\=4)^8=.S'/)R=WM7E];'A74G
MTKQ)93K*L<;2"*8NV%\MCAL\C@=>>,@'M0![M1112`****`"BBB@#RGXH1N/
M$%K*481M:A5;'!(=L@'U&1^8KAZ]9^)6DRWVC07L$<DCV;L7"XP(V'S,1U."
MJ].@R?IY-3`**='&\TJ11(SR.P5549+$]`!W-=YHOPSN9\2ZQ/\`9D_YXPD,
MYZ]6Y4=CQG(/:@#BK'3[O4[E;>RMY)Y3_"@S@9`R3V&2.3Q7;Z3\,+B1EDU:
MZ6*,J#Y5N=SY(/!8C`(..F[//UKT6QT^TTRV6WLK>."(?PH,9.`,D]S@#D\U
M9I`4--T/3-(4"PL886"E=X7+D$YP6/)&?4]A5^BB@`HHHH`****`"BBB@`HH
MHH`*Q_$'ANP\0VCQW$:I<;<1W*J-Z$9QSW7D\>_8\UL44`>#^(/#]WX=U`V]
MP-\;9,,P&%D7^A'<=OH03DU[MXE\/V_B'2WMY$7[0BEK>4G!1\>N#\IXR/Z@
M5X;<6\MI<RV\R[98G,;KD'#`X(R/>F!'1110`4444`%>D_"W4@8K[2V*A@PN
M(Q@Y(.%;)Z8&$_,]>WFU;_@J^^P>+;!RT@25_)8(?O;QM&?4;BI_"@#V^BBB
MD`4444`%%%%`'SC1113`****`"BBB@`HHHH`***GL[.XO[N*UM8FEGE;:B+U
M)_H/?M0!!7=>'_AQ<WR"XU=Y+.(X*PJ!YC`C.3UV\D<$$]>!72^%?`]OHB_:
M;\0W5^6RI`W)$`<C;D?>X!SCCH.Y/7T@*UCI]IIELMO96\<$0_A08R<`9)[G
M`')YJS110`4444`%%%%`!7'>*/`=MK&^ZT\1VU^S[G+$A)<]<@9P>^0.3G/7
M([&B@#YXO+.XL+N6UNHFBGB;:Z-U!_J/?O4%>S>-/"__``D&GK+:I&-0@Y1C
MP9%YRF?KR,]_3)->,TP"BBB@`HHHH`*Z;P+K#Z5XD@B^8P7C""11ZD_*<9`R
M#W]"U<S10!]'450T/4AJ^B6=^"I::,%]H(`<<,!GG`8$5?I`%%%%`!1110`4
M444`5M0OH-,T^>]N&Q%"A=N1D^PSW)X'N:\#U"^GU/4)[VX;,LSEVY.![#/8
M#@>PKOOB9KG^IT6!_26XVG_OE3@_\"((_NFO.*8!1110`4444`%%%7=)TF[U
MK4([*RCWR-R2>%1>[,>P'_UNIH`-)TF[UK4([*RCWR-R2>%1>[,>P'_UNIKU
MGPWX)T_18(IKB*.ZU`?,TS#*H<@X0'I@CAL9Z],X&EX?\/VGAW3Q;VXWRM@S
M3$8:1OZ`=AV^I).M2`****`"BBB@`HHHH`*XK7/AQI]]OGTU_L5P<GR\9B8\
MGIU7DCIP`/NUVM%`'SU?:?=Z9<M;WMO)!*/X7&,C)&0>XR#R.*K5[_JVBV&M
MVC6]]`KC:0D@`WQDXY4]CP/KCG(KQWQ'X5O_``Y*IGVS6TC$1SQ@X)YX8=FQ
MSC\B<&F!A4444`%%%%`!1110`4444`%>U^`O^1+T_P#[:?\`HQJ\4KVOP%_R
M)>G_`/;3_P!&-0!T=%%%(`HHHH`****`"BBB@`HHHH`****`"BBB@#YQHHHI
M@%%%%`!1110!Z/\`"G_F+_\`;'_V>O1Z\X^%/_,7_P"V/_L]>CT@"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`^<:***8!1
M110`4444`>U^`O\`D2]/_P"VG_HQJZ.N<\!?\B7I_P#VT_\`1C5T=(`HHHH`
M****`,?Q7?OIOA?4+J+=Y@CV*5;:5+$*&!]1NS^%>$UZS\3KCR_#L$*S;6EN
M5S&&P74*Q/'<`[?QQ7DU,`HHHH`****`'1QO-*D42,\CL%55&2Q/0`=S7O\`
MI&FQ:/I-MI\)RL*8+<_,W5FP2<9))QVS7DWP_L?MOBV!RL;);(TS!QGH-HQ[
MAF4_A7LU(`HHHH`****`"BBB@`HHHH`****`"J&N::-7T2\L"%+31D)N)`#C
ME2<<X#`&K]%`'SC16[XRM4L_%^I11EBK2"4[CSEU#G\,L:PJ8!1110`4444`
M>_Z'>&_T&PNGE6626!&D=<8+X^;IP#G/':K]<G\.;O[3X2CBV;?LTSQ9SG=D
M[\^WW\?A764@"BBB@`HHHH`;)&DT3Q2HKQNI5E89#`]01W%<O=?#S0+F^%R(
MIH5W;FAB?$;'.3QC(!Z84CCIBNJHH`S=+T#2M&W'3[*.%FSE^68@XXW')QP.
M,XK2HHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"O*_B9I+6^K0ZG'
M'^ZN4"2,,G]XOKV&5QCUVFO5*Y?X@6/VWPE.X61GMG690@ST.TY]@K,?PH`\
M9HHHI@%%%%`!4EO<2VES%<0MMEB<.C8!PP.0<'WJ.B@#Z,CD2:))8G5XW4,K
M*<A@>A![BG5E^&Y$E\,:6T;JZBUC4E3D9"@$?4$$?A6I2`****`"BBB@#YQH
MHHI@%%%%`!1110`445/9V=Q?W<5K:Q-+/*VU$7J3_0>_:@`L[.XO[N*UM8FE
MGE;:B+U)_H/?M7LWA7PK;^'+3<VV6_E7]],!P!_=7T7^?4]@#PKX5M_#EIN;
M;+?RK^^F`X`_NKZ+_/J>P'0T@"BBB@`HHHH`****`"BBB@`HHHH`*\F^(^A_
M8=674H8\6]Y]_:.%E'7H,#<.>N2=QKUFL?Q3I)UKP[=6<:J9]H>'*@G>O(`S
MC!/*Y_VC0!X31113`****`"BBB@#UGX9W_VCP_-9M+N>UF.U-N-J-R.<<Y;?
M[_I7:UY?\++O9J>H6>S/FPK+OSTV'&,>^_\`2O4*0!1110`4444`%-DD2&)Y
M975(T4LS,<!0.I)["G5R?Q#U/[#X9>W1\2WCB(8DVL%ZL<=Q@!3_`+WX$`\H
MU2_?5-4NKZ3<&GD9PK-N*@GA<^@&!^%5***8!1110`4444`%>T>#?#":!IJR
MSQ+_`&E,O[YMV[:,\(#V'3..I[D`5Q'P^\/MJ>K#49ABULG##(/SR=5`(]#@
MG\!CFO7:0!1110`4444`%%%%`!1110`4444`%07EG;W]I+:W42RP2KM=&Z$?
MT/OVJ>B@#Q+Q5X5N/#EWN7=+82M^YF(Y!_NMZ-_/J.X'/5]#WEG;W]I+:W42
MRP2KM=&Z$?T/OVKQGQ5X5N/#EWN7=+82M^YF(Y!_NMZ-_/J.X#`YZBBB@`HH
MHH`****`"O:_`7_(EZ?_`-M/_1C5XI7M?@+_`)$O3_\`MI_Z,:@#HZ***0!1
M110`4444`%%%%`!1110`4444`%%%%`'SC1113`****`"BBB@#T?X4_\`,7_[
M8_\`L]>CUYQ\*?\`F+_]L?\`V>O1Z0!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`?.-%%%,`HHHH`****`/:_`7_(EZ?_VT
M_P#1C5T=<YX"_P"1+T__`+:?^C&KHZ0!1110`4444`><?%;_`)A'_;;_`-DK
MSBNZ^*-Q*VN6=N6_=1VV]5P.&9B"<_15_*N%I@%%%%`!1110!Z+\*HT,NJRE
M%,BK$JMCD`[\@'T.!^0KTFN*^&'_`"+5S_U^-_Z`E=K2`****`"BBB@`HHHH
M`****`"BBB@`HHHH`\I^*$;CQ!:RE&$;6H56QP2';(!]1D?F*X>O1_BM_P`P
MC_MM_P"R5YQ3`****`"BBB@#U3X77$3:'>6X;]['<[V7!X5E`!S]5;\J[JO.
M/A3_`,Q?_MC_`.SUZ/2`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`JMJ%I]OTRZL]^S[1"\6_&=NX$9QWZU9HH`^<:*GO+
M5[&^N+24J9()&B8J>"5.#CVXJ"F`4444`%%%%`'M?@+_`)$O3_\`MI_Z,:NC
MKF?`$B/X,LE1U9D:17`.2IWL<'T."#^(KIJ0!1110`4444`?.-%%%,`HHHH`
M****`'1QO-*D42,\CL%55&2Q/0`=S7M/A'PO!X?T]9)$SJ$R`SNV,IWV#'8'
M\R,^@&)\-_#\4-E_;<PCDEFRMOP<Q*"58_4D8^@Z\D5WU(`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`\'\3V/\`9WB;4+8+&JB8NBQC"JK?,H`[8!`K
M)KN/B?9F+7K:Z$2K'/!M+C&7=2<Y[Y`*<GV]*X>F`4444`%%%%`'4?#ZXEA\
M8VL<;869)$D&!RNTMC\U!_"O9J\)\*73V?BO3)8PI9IUB.X<8?Y#^.&->[4@
M"BBB@`HHHH`*\I^)NI"YUNWL$*E;2/+<$$.^"0>Q&T(>/4_AZM7@?B"__M3Q
M!?7@E\U))F\M]NW*#A>,#^$#WH`S:***8!1110`445M^$M,_M;Q-96[)NB5_
M-ES'O7:O.&'H2`O/][\*`/6/"FB_V%X?@M7&+A_WL_/\9ZCJ1P`!QP<9[UMT
M44@"BBB@`HHHH`****`"BBB@`HHHH`****`"H+RSM[^TEM;J)98)5VNC="/Z
M'W[5/10!X9XH\/R^'=6>WQ(UJ_S6\K@?.O<<=P3@].QP,BL2O?\`6M)M];TN
M:QN%7#J=CE<F-\<,.G(^O/(Z&O`*8!1110`4444`%>U^`O\`D2]/_P"VG_HQ
MJ\4KVOP%_P`B7I__`&T_]&-0!T=%%%(`HHHH`****`"BBB@`HHHH`****`"B
MBB@#YQHHHI@%%%%`!1110!Z/\*?^8O\`]L?_`&>O1Z\X^%/_`#%_^V/_`+/7
MH](`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`/G&BBBF`4444`%%%%`'M?@+_D2]/\`^VG_`*,:NCKG/`7_`")>G_\`;3_T
M8U='2`****`"BBB@#RGXH1N/$%K*481M:A5;'!(=L@'U&1^8KAZ]'^*W_,(_
M[;?^R5YQ3`****`"BBB@#UGX8?\`(M7/_7XW_H"5VM>;?"J1!+JL1=1(RQ,J
MYY(&_)`]!D?F*])I`%%%%`!1110`4444`%%%%`!1110`4444`>7_`!3N]^IZ
M?9[,>5"TN_/7><8Q[;/UK@:ZKXB73W'B^>)PH6WCCB3`Y(*[^??+G]*Y6F`4
M444`%%%%`'IGPKMY5MM3N"O[J1XXU;(Y90Q(Q]&7\Z]"KBOAA_R+5S_U^-_Z
M`E=K2`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`\#\0_\C+JO_7Y-_P"AFLVM+Q#_`,C+JO\`U^3?^AFLVF`4444`
M%%%%`'K/PP_Y%JY_Z_&_]`2NUKBOAA_R+5S_`-?C?^@)7:T@"BBB@`HHHH`^
M<:***8!1110`4444`>U^`O\`D2]/_P"VG_HQJZ.N<\!?\B7I_P#VT_\`1C5T
M=(`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`\_\`BG:N]CIUV"OEQ2/$
MPSSE@",>WR']*\QKUGXG_P#(M6W_`%^+_P"@/7DU,`HHHH`****`-+P]_P`C
M+I7_`%^0_P#H8KWROGK3[O[!J=K>;-_V>9)=F<;MI!QGMTKZ%I`%%%%`!111
M0!4U6Z>QTB]NX@ID@@DE4,."54D9]N*^?*]K\>7'V?P=?8F\IY-D:X;:6RPR
MH]<KNR/3->*4P"BBB@`HHHH`*]'^%EA_R$-1>+^[!')N_P"!.,9_W.<?3O7G
M%>R?#NU2W\(02H6+7$DDKY/`(;9Q[80?K0!U5%%%(`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`*^<:^CJ^<:`"BBBF`4444`%>U^`O^1+T__MI_Z,:O
M%*]K\!?\B7I__;3_`-&-0!T=%%%(`HHHH`****`"BBB@`HHHH`****`"BBB@
M#YQHHHI@%%%%`!1110!Z/\*?^8O_`-L?_9Z]'KSCX4_\Q?\`[8_^SUZ/2`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#YQH
MHHI@%%%%`!1110![7X"_Y$O3_P#MI_Z,:NCKG/`7_(EZ?_VT_P#1C5T=(`HH
MHH`****`.*^)UOYGAV"98=S17*YD"Y**58'GL"=OXXKR:O>/$]C_`&CX9U"V
M"R,QA+HL8RS,OS*`.^2`*\'I@%%%%`!1110!TW@+4AIWBNW#E1'=*;=B0206
MP5QCN6"C\3]:]HKYSCD>&5)8G9)$8,K*<%2.A![&O>/#VL)KNB6]\NT2,NV9
M5_AD'WAC)P.XSS@BD!J4444`%%%%`!1110`4444`%%%%`!4=Q<16EM+<3MMB
MB0N[8)PH&2<#VJ2N*^(^N?8=)7387Q<7GW]IY6(=>AR-QXZ8(W"@#RV\NGOK
MZXNY0HDGD:5@HX!8Y./;FH***8!1110`445);V\MW<Q6\*[I97$:+D#+$X`R
M?>@#VOP3;RVW@[3HYEVL4:0#(/RLQ93QZ@@UOU';V\5I;16\"[8HD$:+DG"@
M8`R?:I*0!1110`4444`%%%%`!1110`4444`%%%%`!152ZU73K&417=_:V\A7
M<%EF5"1ZX)Z<&L"Z^(GAZWB#Q7$URQ;&R*%@0/7YMHQ^/>@#JJ*\_NOBG:I*
M!::7-+'MY:641G/I@!N.G.:S;KXI:B\H-II]K%'MY64M(<^N05XZ<8H`]2HK
MR23XFZX\3HL-C&S*0'6-LJ?498C/U!JA_P`)[XE_Z"7_`)`C_P#B:`/:J*\5
M_P"$]\2_]!+_`,@1_P#Q-'_">^)?^@E_Y`C_`/B:`/:J*\5_X3WQ+_T$O_($
M?_Q-'_">^)?^@E_Y`C_^)H`]JHKQ7_A/?$O_`$$O_($?_P`31_PGOB7_`*"7
M_D"/_P")H`S?$/\`R,NJ_P#7Y-_Z&:S:DN+B6[N9;B9MTLKEW;`&6)R3@>]1
MTP"BBB@`HHHH`]9^&'_(M7/_`%^-_P"@)7:UQ7PP_P"1:N?^OQO_`$!*[6D`
M4444`%%%%`'SC1113`****`"BBB@#VOP%_R)>G_]M/\`T8U='7.>`O\`D2]/
M_P"VG_HQJZ.D`4444`%%%%`!1110`4444`%%%%`!1110`4444`<G\1K3[3X2
MDEW[?LTR2XQG=D[,>WW\_A7CM>U^/?\`D2]0_P"V?_HQ:\4I@%%%%`!1110`
M5]'5\XU]'4@"BBB@`HHHH`XCXH2(/#]K$742-=!E7/)`1LD#T&1^8KRBO1_B
MM_S"/^VW_LE><4P"BBB@`HHHH`*]_P!"C>'P_IL4J,DB6L2LK#!4A!D$=C7@
M%?1U(`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"OG&OHZOG&@`
MHHHI@%%%%`!7M?@+_D2]/_[:?^C&KQ2O:_`7_(EZ?_VT_P#1C4`='1112`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`^<:***8!1110`4444`>C_"G_F+_P#;
M'_V>O1Z\X^%/_,7_`.V/_L]>CT@"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`^<:***8!1110`4444`>U^`O^1+T_\`[:?^
MC&KHZYSP%_R)>G_]M/\`T8U='2`****`"BBB@`KPSQ7HO]A>()[5!BW?][!S
M_`>@ZD\$$<\G&>]>YUQWQ!\/KJ>DG481BZLD+'`'SQ]6!)]!DC\1CF@#R*BB
MBF`4444`%=1X+\4?\(_J#173R'3Y^'4<B-N,/CZ<'';UP!7+T4`?1D<B31)+
M$ZO&ZAE93D,#T(/<4ZO(/!OC)]#E6RO69]-=N#U,!/<>J^H_$<Y!]8L[RWO[
M2*ZM95E@E7<CKT(_H?;M2`GHHHH`****`"BBB@`HHK-UG7=/T&V$U_-LWY$<
M:C+2$#.`/ZG`Y&2,T`2ZMJUIHNGR7M[)LB7@`<L[=E4=R?\`Z_05X=K6KW&M
MZI-?7#-EV.Q"V1&F>%'3@?3GD]34WB#Q!=^(M0-Q<'9&N1#"#E8U_J3W/?Z`
M`9-,`HHHH`****`"NL^'FF?;O$R7#IF*S0RG,>Y2W11GL<DL/]W\1R=>U^"=
M#_L7P_'YL>V[N<2S9&"N?NJ>`>!V/0EJ`.CHHHI`%%%%`!1110`4444`%%%8
M'B#Q=IOA]"DC^?=G(%O$PW`XR-W]T<CWYX!H`WZPM6\7Z+HZL)KM9IE8J8+<
MAW!!`(/.%(SW(Z&O,M<\;:OK6^+S?LMHV1Y,)QN'/#-U;@X(X!QTKFZ`.^U/
MXGW<NZ/3+..!?F`EF.]L?PL`,`'O@[A_7E[[Q/K>H[A<ZG<%638R(WEJR\Y!
M5<`]>XK)HI@%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`>
ML_##_D6KG_K\;_T!*[6N*^&'_(M7/_7XW_H"5VM(`HHHH`****`/G&BBBF`4
M444`%%%%`'M?@+_D2]/_`.VG_HQJZ.N<\!?\B7I__;3_`-&-71T@"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@#G/'O\`R)>H?]L__1BUXI7M?CW_`)$O
M4/\`MG_Z,6O%*8!1110`4444`%?1U?.-?1U(`HHHH`****`/+?BE=.^KV-H0
MOEQ0&53CG+,0<^WR#]:X.NU^)_\`R,MM_P!>:_\`H;UQ5,`HHHH`****`-+P
M]_R,NE?]?D/_`*&*]\KP/P]_R,NE?]?D/_H8KWRD`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!7SC7T=7SC0`4444P"BBB@`KVOP%_R)>G_P#;
M3_T8U>*5[7X"_P"1+T__`+:?^C&H`Z.BBBD`4444`%%%%`!1110`4444`%%%
M%`!1110!\XT444P"BBB@`HHHH`]'^%/_`#%_^V/_`+/7H]><?"G_`)B__;'_
M`-GKT>D`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`'SC1113`****`"BBB@#VOP%_R)>G_]M/\`T8U='7.>`O\`D2]/_P"V
MG_HQJZ.D`4444`%%%%`!1110!XOXR\,/H&I-+!$W]FS-^Y;=NVG'*$]CUQGJ
M.Y(-<S7JGQ#U_3XM/?2##'=7DF&P>EOZ-D?Q8Z#T//!P?*Z8!1110`4444`%
M7=-U?4-'G,VGW<D#'[P4Y5N".5/!ZGJ.*I44`>DZ;\4D*A=4T]@P4YDM3D$Y
MX&UCP,=]QZ>_'56GB_P_>[_*U6W79C/G$Q=?3?C/3M7AE%`'T5;W$%W`LUO-
M'-$V=LD;!E.#C@CWJ2OG&BD!]#W5Y:V,0EN[F&WC+;0TL@0$^F3WX-8]]XU\
M/V&X/J,<SA-X6W!DW=>,CY0>.Y%>(44P/0-6^)]Q(S1Z3:K%&5(\VX&Y\D#D
M*#@$'/7=GCZ5P=Q<3W<[37$TDTK8W22,68X&.2?:HZ*`"BBB@`HHHH`***NZ
M3I-WK6H1V5E'OD;DD\*B]V8]@/\`ZW4T`;O@?PV=;U07-Q&WV"V8,Q*@K(X(
M(3GJ.YX/''&0:]DJEI.DVFBZ?'964>R)>23RSMW9CW)_^MT%7:0!1110`444
M4`%%%%`!39)$AB>65U2-%+,S'`4#J2>PHDD2&)Y975(T4LS,<!0.I)["O(O&
M7C)]<E:RLF9--1N3T,Y'<^B^@_$\X``-3Q1\0VEWV>AOB)DP]V5*MD_W,XQQ
MD9(SSQC`)\\HHI@%%%%`!1110`4444`%%%%`!16A'H6KS1)+%I5\\;J&5EMW
M(8'H0<<BK=IX0\07N_RM*N%V8SYP$77TWXST[4`8E%=)_P`(%XE_Z!O_`)'C
M_P#BJ/\`A`O$O_0-_P#(\?\`\50!S=%=)_P@7B7_`*!O_D>/_P"*H_X0+Q+_
M`-`W_P`CQ_\`Q5`'-T5TG_"!>)?^@;_Y'C_^*H_X0+Q+_P!`W_R/'_\`%4`<
MW14EQ;RVES+;S+MEB<QNN0<,#@C(]ZCH`****`"BBB@#UGX8?\BU<_\`7XW_
M`*`E=K7%?##_`)%JY_Z_&_\`0$KM:0!1110`4444`?.-%%%,`HHHH`****`/
M:_`7_(EZ?_VT_P#1C5T=<YX"_P"1+T__`+:?^C&KHZ0!1110`4444`%%%%`!
M1110`4444`%%%%`!1110!SGCW_D2]0_[9_\`HQ:\4KVOQ[_R)>H?]L__`$8M
M>*4P"BBB@`HHHH`*^CJ^<:^CJ0!1110`4444`>3?$_\`Y&6V_P"O-?\`T-ZX
MJNU^)_\`R,MM_P!>:_\`H;UQ5,`HHHH`****`-+P]_R,NE?]?D/_`*&*]\KP
M/P]_R,NE?]?D/_H8KWRD`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!7SC7T=7SC0`4444P"BBB@`KVOP%_R)>G_P#;3_T8U>*5[7X"_P"1+T__
M`+:?^C&H`Z.BBBD`4444`%%%%`!1110`4444`%%%%`!1110!\XT444P"BBB@
M`HHHH`]'^%/_`#%_^V/_`+/7H]><?"G_`)B__;'_`-GKT>D`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'SC1113`****`"
MBBB@#VOP%_R)>G_]M/\`T8U='7.>`O\`D2]/_P"VG_HQJZ.D`4444`%%%%`!
M6%XJ\1IX<TOSPBR7,K;((R<`G'+$==H[X]0.,YK;DD2&)Y975(T4LS,<!0.I
M)["O"?$FMRZ_K,MX_$8^2!=H!6,$X!Z\\DGGJ?3%`&;<7$MW<RW$S;I97+NV
M`,L3DG`]ZCHHI@%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`445
MU'AOP3J&M3Q37$4EKIY^9IF&&<8!P@/7(/#8QUZXP0#$TG2;O6M0CLK*/?(W
M))X5%[LQ[`?_`%NIKVOP_P"'[3P[IXM[<;Y6P9IB,-(W]`.P[?4DFSI.DVFB
MZ?'964>R)>23RSMW9CW)_P#K=!5VD`4444`%%%%`!1110`445E^(=830M$N+
MYMID5=L*M_%(?NC&1D=SCG`-`''?$3Q.\3'1+*5D8K_I;!<'!`(0'T(.3]0,
M]17FU.DD>:5Y979Y'8LS,<EB>I)[FFTP"BBB@`HHHH`**='&\TJ11(SR.P55
M49+$]`!W->C^&_APGE?:->5O,W';:I)P!R,LR]3W`![<YS@`'#:;H>IZNP%A
M8S3*6*[PN$!`S@L>`<>I[BNUTWX6N6#:IJ"A0QS':C)(QP=S#@Y[;3T]^/1X
MXTAB2*)%2-%"JJC`4#H`.PIU(#`L?!7A^PVE-.CF<)L+7!,F[IS@_*#QV`K;
MM[>"T@6&WACAB7.V.-0JC)SP![U)10`4444`%%%%`!1110`4444`>!^(?^1E
MU7_K\F_]#-9M:7B'_D9=5_Z_)O\`T,UFTP"BBB@`HHHH`]9^&'_(M7/_`%^-
M_P"@)7:UQ7PP_P"1:N?^OQO_`$!*[6D`4444`%%%%`'SC1113`****`"BBB@
M#VOP%_R)>G_]M/\`T8U='7.>`O\`D2]/_P"VG_HQJZ.D`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`<YX]_Y$O4/^V?_`*,6O%*]K\>_\B7J'_;/_P!&
M+7BE,`HHHH`****`"OHZOG&OHZD`4444`%%%%`'E?Q1MY5URSN"O[J2V\M6R
M.65B2,?1E_.N%KT?XK?\PC_MM_[)7G%,`HHHH`****`)+>XEM+F*XA;;+$X=
M&P#A@<@X/O7T57SC7T+I]W]OTRUO-FS[1"DNS.=NX`XSWZT@+-%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`5\XU]'5\XT`%%%%,`HHHH`*]K\!?
M\B7I_P#VT_\`1C5XI7M?@+_D2]/_`.VG_HQJ`.CHHHI`%%%%`!1110`4444`
M%%%%`!1110`4444`?.-%%%,`HHHH`****`/1_A3_`,Q?_MC_`.SUZ/7G'PI_
MYB__`&Q_]GKT>D`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`'SC1113`****`"BBB@#VOP%_P`B7I__`&T_]&-71USG@+_D
M2]/_`.VG_HQJZ.D`4444`%%%%`'`_$S6O(LH='B/SW&)9N.B`_*.G=AG@Y&W
MWKR^M;Q+JS:SX@N[OS-\6\I#C(`C'"X!Z9')]R:R:8!1110`445UGP^T7^U/
M$`NI!FWL<2GGJ_\``.H/4$]Q\N#UH`Z_P=X,M]/TTW.HPK/<W<8WPRIE8TR&
M"E3U;(!.1P1@=,G+USX9_?GT6?U/V:8_4X5OR`!_%J]'HI`?/5]I]WIERUO>
MV\D$H_A<8R,D9![C(/(XJM7T5<6\%W`T-Q#'-$V-T<BAE.#GD'WKF;_X>:!>
MR^8D4UHQ8LPMWP&)]F!``[`8ZTP/&Z*[Z[^%EZFS['J5O-G._P`Y&CQZ8QNS
MW]*QY/`'B1)71;!9%5B`ZSIAAZC)!Q]0*`.9HK6N/"^NVT[0R:3>%EQDQQ&1
M>F>&7(/YU'_PCVM_]`?4/_`9_P#"@#-HK6M_"^NW,ZPQZ3>!FS@R1&->F>6;
M`'YU>_X0+Q+_`-`W_P`CQ_\`Q5`'-T5W5O\`"[5&G47%]9QQ<[FCW.PX[`@9
MY]ZVK'X8:;#M:]O+BY8/G"`1J5X^4CD^O((ZT`>5UOZ3X,UO5TCEAM?)MWZ3
M3G8N,9!`^\0<C!`(KUO3?#FCZ2P>RT^&.0,6$A&]P2,'#-D@8[9]?6M2D!R>
MB_#[2-+Q)=+]ON!_%,OR#KT3D=".N>1D8KK***`"BBB@`HHHH`****`"BBB@
M`KROXF:LUQJT.F1R?NK9`\BC(_>-Z]CA<8]-QKU2OG[6+[^T]9O+T-(5FF9T
M\P_,%S\H/T&!^%`%*BBBF`4444`%%%=1X#T2+6/$`-S%YEK;(975D)5FZ*I/
MUYP>NTC'6@#L_`WA--*M(]2O86&HRJ=JR#!@4]@/[Q'4]1G''.>SHHI`%%%%
M`!1110`4444`%%%%`!1110`4444`>!^(?^1EU7_K\F_]#-9M:7B'_D9=5_Z_
M)O\`T,UFTP"BBB@`HHHH`]9^&'_(M7/_`%^-_P"@)7:UQ7PP_P"1:N?^OQO_
M`$!*[6D`4444`%%%%`'SC1113`****`"BBB@#VOP%_R)>G_]M/\`T8U='7.>
M`O\`D2]/_P"VG_HQJZ.D`4444`%%%%`!1110`4444`%%%%`!1110`4444`<Y
MX]_Y$O4/^V?_`*,6O%*]K\>_\B7J'_;/_P!&+7BE,`HHHH`****`"OHZOG&O
MHZD`4444`%%%%`'"_%&WB;0[.X*_O8[GRU;)X5E)(Q]57\J\KKV;X@V\4W@Z
MZDD7+0O')&<GAMP7/Y,1^->,TP"BBB@`HHHH`*]S\(7?VWPEILNS9MA$6,Y^
MX2F?QVY_&O#*];^&=X9_#<EN\JLUO.RJG&40@,,]\%B_)]_2@#LZ***0!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`5\XU]'5\XT`%%%%,`HHHH`*]K\
M!?\`(EZ?_P!M/_1C5XI7M?@+_D2]/_[:?^C&H`Z.BBBD`4444`%%%%`!1110
M`4444`%%%%`!1110!\XT444P"BBB@`HHHH`]'^%/_,7_`.V/_L]>CUYQ\*?^
M8O\`]L?_`&>O1Z0!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`?.-%%%,`HHHH`****`/:_`7_(EZ?\`]M/_`$8U='7.>`O^
M1+T__MI_Z,:NCI`%%%%`!5#7+PV&@W]TDJQ210.T;MC`?'R]>"<XX[U?KG/'
MO_(EZA_VS_\`1BT`>*4444P"BBB@`KUOX9V9@\-R7#Q*K7$[,K\9=``HSWP&
M#\'W]:\DKVCP!(C^#+)4=69&D5P#DJ=['!]#@@_B*`.FHHHI`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!0UV1X?#^I2Q.
MR2):RLK*<%2$."#V->`5[7X]_P"1+U#_`+9_^C%KQ2F`4444`%%%%`!7KOPV
ML?LWADW++'NNIF<,H^;:OR@$^Q#'\?>O(J]V\*6J6?A33(HRQ5H%E.X\Y?YS
M^&6-`&Q1112`****`"BBB@`HHHH`****`"BBB@`HHHH`\#\0_P#(RZK_`-?D
MW_H9K-K2\0_\C+JO_7Y-_P"AFLVF`4444`%%%%`'K/PP_P"1:N?^OQO_`$!*
M[6N*^&'_`"+5S_U^-_Z`E=K2`****`"BBB@#YQHHHI@%%%%`!1110![7X"_Y
M$O3_`/MI_P"C&KHZYSP%_P`B7I__`&T_]&-71T@"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@#G/'O_(EZA_VS_\`1BUXI7M?CW_D2]0_[9_^C%KQ2F`4
M444`%%%%`!7T=7SC7T=2`****`"BBB@"EK-O+=Z'J%O"NZ66VDC1<@98J0!D
M^]?/U?1U?/VL6/\`9FLWED%D"PS,B>8/F*Y^4GZC!_&@"E1113`****`"NZ^
M&%]Y.LW=DS1JMQ"'&XX8LAX`_!F/X>U<+6AH>I'2-;L[\%@L,@+[0"2AX8#/
M&2I(H`]^HIL<B31)+$ZO&ZAE93D,#T(/<4ZD`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`07EY;V%I+=74JQ01+N=VZ`?U/MWKYXKL?&WBZ75[F33K1]
MNGQ.0Q5@?/8'[V1_#GH/Q],<=3`****`"BBB@`KVOP%_R)>G_P#;3_T8U>*5
M[7X"_P"1+T__`+:?^C&H`Z.BBBD`4444`%%%%`!1110`4444`%%%%`!1110!
M\XT444P"BBB@`HHHH`]'^%/_`#%_^V/_`+/7H]><?"G_`)B__;'_`-GKT>D`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'S
MC1113`****`"BBB@#VOP%_R)>G_]M/\`T8U='7.>`O\`D2]/_P"VG_HQJZ.D
M`4444`%<=\2_/_X19/*\S9]I3S=F<;<-][VW;>O?%=C7/>.8WE\&:BL:,[!4
M8A1DX#J2?H`"?PH`\2HHHI@%%%%`!7>?#;7DL[N72;F14BN6#P%C@>9P"O3J
MPQU/\.!R:X.B@#Z.HKS;PQ\1!%%%9:V6*HI`O.6.!T#@#)/4;A[9'4UZ%:WE
MK?1&6TN8;B,-M+12!P#Z9'?D4@)Z***`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@#G/'O\`R)>H?]L__1BUXI7M_C:WEN?!VHQP
MKN8(LA&0/E5@S'GT`)KQ"F`4444`%%%%`!7O'A>XBN?"VER0MN46R(3@CYE&
MUASZ$$5X/7LGP[NDN/"$$2!@UO))$^1P26W\>V''ZT`=51112`****`"BBB@
M`HHHH`****`"BBB@`ILDB0Q/+*ZI&BEF9C@*!U)/84ZO*_'GBZ+4\Z5I[[K6
M-P99E8XE8?PCU4'G/<@8Z9(!R6LW$5WKFH7$#;HI;F1T;!&5+$@X/M5*BBF`
M4444`%%%%`'K/PP_Y%JY_P"OQO\`T!*[6N*^&'_(M7/_`%^-_P"@)7:T@"BB
MB@`HHHH`^<:***8!1110`4444`>U^`O^1+T__MI_Z,:NCKG/`7_(EZ?_`-M/
M_1C5T=(`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`YSQ[_R)>H?]L_\`
MT8M>*5[7X]_Y$O4/^V?_`*,6O%*8!1110`4444`%?1U?.-?1U(`HHHH`****
M`"O(OB38_9O$PN563;=0JY9A\NY?E(!]@%/X^]>NUQGQ*TT77AU+T!?,LY`2
M23G8V%(`Z$YV'GT/X@'DE%%%,`HHHH`****`/8OA]K7]J>'Q:R'-Q8XB/'5/
MX#T`Z`CN?ER>M=97AGA36O["\0073G%N_P"ZGX_@/4]">"`>.3C'>O<8Y$FB
M26)U>-U#*RG(8'H0>XI`.HHHH`****`"BBB@`HHHH`****`"BBB@`KS'QUXR
M>:6?1=.9DB1C'<R]"Y'!0>B]B>_3IUT/&WC;['YFE:5+_I/*SW"G_5>JJ?[W
MJ>WUZ>7T`%%%%,`HHHH`****`"O:_`7_`")>G_\`;3_T8U>*5[7X"_Y$O3_^
MVG_HQJ`.CHHHI`%%%%`!1110`4444`%%%%`!1110`4444`?.-%%%,`HHHH`*
M***`/1_A3_S%_P#MC_[/7H]><?"G_F+_`/;'_P!GKT>D`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'SC1113`****`"BBB
M@#VOP%_R)>G_`/;3_P!&-71USG@+_D2]/_[:?^C&KHZ0!1110`5!>6J7UC<6
MDI81SQM$Q4\@,,''OS4]%`'SQ>6KV-]<6DI4R02-$Q4\$J<''MQ4%>A_$GP^
MR3C78!E'VQW"@$D-C`?/0#`"]N<=<UYY3`****`"BBB@`J2WN)[2=9K>:2&5
M<[9(V*L,C'!'M4=%`&_;^-O$=M`L,>J2%5S@R(LC=<\LP)/YUK?\+/UO_GUT
M_P#[]O\`_%UQ5%`'H=O\5)U@47&DQR2\[FCG**>>P(../>I/^%K?]07_`,FO
M_L*\XHH`]'_X6M_U!?\`R:_^PJ[;_%'2V@4W%C>1R\[ECVNHY[$D9X]J\KHH
M`]9_X6?HO_/KJ'_?M/\`XNC_`(6?HO\`SZZA_P!^T_\`BZ\FHH`]FM_B#X<F
M@622[D@8YS')"Q8<]]H(_6I?^$]\-?\`02_\@2?_`!->*44`>U_\)[X:_P"@
ME_Y`D_\`B:OQ^)-#EB21=7L0KJ&`:=5.#Z@G(/L:\%HH`^A[6\M;Z(RVES#<
M1AMI:*0.`?3([\BIZ^<:T+/7-5L%B2UU&ZBCB;<D:RG8#G/W>A&>V.:0'OU%
M>16/Q)UNVVK<BWNUWY8NFQMO&5!7`'U(/7O75:;\2M'NE`O4FLI-I))7S$SG
M@`KR3CG[H[_B`=G14=O<07<"S6\T<T39VR1L&4X.."/>I*`"BBB@`HHHH`J:
MK:O?:1>VD1423P21*6/`+*0,^W-?/E?1U>!^(+#^R_$%]9B+RDCF;RTW;L(>
M5YR?X2/>@#-HHHI@%%%%`!79_#C6$L-;DL9MJQWRA58\8D7.T9)Z')'<D[:X
MRG1R/#*DL3LDB,&5E."I'0@]C0!]&45@>%/$T7B33V<IY5W!@3Q@';DYPRGT
M.#QU&/H3OT@"BBB@`HHHH`****`"BBB@`ILDB0Q/+*ZI&BEF9C@*!U)/856U
M+4[+2+0W5_<+#"&"[B"22>P`Y)^GH:\D\4>-+OQ!OM8E^SZ>'RL8^](!TWG/
MKS@<?7`-`&AXL\>OJD4NG:8&BM"Q5Y\X:9?0#^%3S[D8Z<BN'HHI@%%%%`!1
M110`4444`>L_##_D6KG_`*_&_P#0$KM:XKX8?\BU<_\`7XW_`*`E=K2`****
M`"BBB@#YQHHHI@%%%%`!1110![7X"_Y$O3_^VG_HQJZ.N<\!?\B7I_\`VT_]
M&-71T@"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#G/'O_(EZA_VS_P#1
MBUXI7M?CW_D2]0_[9_\`HQ:\4I@%%%%`!1110`5]'5\XU]'4@"BBB@`HHHH`
M*@O+5+ZQN+24L(YXVB8J>0&&#CWYJ>B@#YXO+5[&^N+24J9()&B8J>"5.#CV
MXJ"N^^)FB^1>PZQ$/DN,13<]'`^4]>ZC'`P-OO7`TP"BBB@`HHHH`*])^'_B
MQ/*31=0F;S-V+61SP1VCSV/IGUQQ@`^;44`?1U%<1X3\>IJDL6G:F%BNRH5)
M\X69O0C^%CQ[$YZ<"NWI`%%%%`!1110`4444`%%%4-6UJPT2T:XOIU0;24C!
M&^0C'"CN>1],\X%`%V21(8GEE=4C12S,QP%`ZDGL*\Q\;>-OMGF:5I4O^C<K
M/<*?];ZJI_N^I[_3KD^*/&EWX@WVL2_9]/#Y6,?>D`Z;SGUYP./K@&N7I@%%
M%%`!1110`4444`%%%%`!7M?@+_D2]/\`^VG_`*,:O%*]K\!?\B7I_P#VT_\`
M1C4`='1112`****`"BBB@`HHHH`****`"BBB@`HHHH`^<:***8!1110`4444
M`:6DZ]J>A^=_9USY/G;?,_=JV<9Q]X'U-:7_``GOB7_H)?\`D"/_`.)KFZ*`
M.D_X3WQ+_P!!+_R!'_\`$T?\)[XE_P"@E_Y`C_\`B:YNB@#I/^$]\2_]!+_R
M!'_\31_PGOB7_H)?^0(__B:YNB@#I/\`A/?$O_02_P#($?\`\31_PGOB7_H)
M?^0(_P#XFN;HH`Z3_A/?$O\`T$O_`"!'_P#$T?\`">^)?^@E_P"0(_\`XFN;
MHH`Z3_A/?$O_`$$O_($?_P`31_PGOB7_`*"7_D"/_P")KFZ*`.D_X3WQ+_T$
MO_($?_Q-'_">^)?^@E_Y`C_^)KFZ*`.D_P"$]\2_]!+_`,@1_P#Q-'_">^)?
M^@E_Y`C_`/B:YNB@#I/^$]\2_P#02_\`($?_`,31_P`)[XE_Z"7_`)`C_P#B
M:YNB@#V3P?XP'B-9+:YB6*_B4N1&#L=,XR,YP1D`@GW'<#JJ\'\+W$MMXITN
M2%MK&Y1"<`_*QVL.?4$BO>*0!1110`4444`?.-%%%,`HHHH`****`/:_`7_(
MEZ?_`-M/_1C5T=<YX"_Y$O3_`/MI_P"C&KHZ0!1110`4444`1W%O%=VTMO.N
MZ*5#&ZY(RI&",CVKQ;Q5X5N/#EWN7=+82M^YF(Y!_NMZ-_/J.X'MM-DC2:)X
MI45XW4JRL,A@>H([B@#YSHKT/Q!\-I4<SZ$?,0Y+6TK@,#G^%CP1@]SGCJ<U
MY])&\,KQ2HR2(Q5E88*D=01V-,!M%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`%FQU"[TRY6XLKB2"4?Q(<9&0<$=QD#@\5Z!X?^)0
M=DM]<14&W_CZC4XR`/O(,\GGD>HX`YKS:B@#Z*M[B"[@6:WFCFB;.V2-@RG!
MQP1[U)7AGA_Q1J'AV<?9WWVK.&EMV^Z_&.#_``G'<>@SG&*]FTG5K36M/CO;
M*3?$W!!X9&[JP[$?_7Z&D!=HHHH`*\T^)^DK'/::K%'CS<PS,,`%@,J<=22-
MPSZ*.E>EU2U?38M8TFYT^8X69,!N?E;JK8!&<$`X[XH`^?J*GO+.XL+N6UNH
MFBGB;:Z-U!_J/?O4%,`HHHH`****`+-CJ%WIERMQ97$D$H_B0XR,@X([C('!
MXKUOPUXXL-;5+>Y*VM_M`*.0$D8G'R$GD].#SSQG!->-T4`?1U%>(:3XSUO2
M$CBANO.MTZ0SC>N,8`!^\`,#`!`KK;'XIP-M74--D3"<O;N&W-Q_"<8'7N?Q
MZT@/0J*Y"U^)&@7$I24W5LH7.^6+()]/E+'/X=JN?\)[X:_Z"7_D"3_XF@#H
MZ*XK_A9^B_\`/KJ'_?M/_BZQ+OXIWK[/L>FV\.,[_.=I,^F,;<=_6@#TZ21(
M8GEE=4C12S,QP%`ZDGL*XS7/B/I]COATU/MMP,CS.D2GD=>K<@=."#]ZO.-4
MU_5=9VC4+V295QA.%4$9YVC`SR><9K-I@7=2U?4-8G$VH7<D[#[H8X5>`.%'
M`Z#H.:I444`%%%%`!13HXWE8K&C.P4L0HR<`9)^@`)_"FT`%%%%`!1110!ZS
M\,/^1:N?^OQO_0$KM:XKX8?\BU<_]?C?^@)7:T@"BBB@`HHHH`^<:***8!11
M10`4444`>U^`O^1+T_\`[:?^C&KHZYSP%_R)>G_]M/\`T8U='2`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`.<\>_P#(EZA_VS_]&+7BE>U^/?\`D2]0
M_P"V?_HQ:\4I@%%%%`!1110`5]'5\XU]'4@"BBB@`HHHH`****`*6KZ;%K&D
MW.GS'"S)@-S\K=5;`(S@@''?%>#ZA8SZ9J$]E<+B6%RC<'!]QGL1R/8U]"UP
M?Q$\-BZM#K-K&HG@7_2`JG=(G`#<=U_EW^4"@#RVBBBF`4444`%%%%`!79^'
M_B'?Z:J6^HJU];[O]8SGS5!([G[P'/!]>H`KC**`/=M)\4Z/K3+'9WB^>5!\
MF0;'S@G`!^\1@YQFMBOG&M"SUS5;!8DM=1NHHXFW)&LIV`YS]WH1GMCFD![]
M17BO_">^)?\`H)?^0(__`(FC_A/?$O\`T$O_`"!'_P#$T`>U50U+7-,TA2;^
M]AA8*&V%LN03C(4<D9]!V->*7GB36K]I3<:G=,LJ[719"J$8QC:,#&/;FLN@
M#T?7/B9]^#18/4?:9A]1E5_(@G\5K@;[4+O4[EKB]N))Y3_$YS@9)P!V&2>!
MQ5:BF`4444`%%%%`!3A&YB:4(QC5@K-C@$YP"?4X/Y&M3P_X?N_$6H"WMQLC
M7!FF(RL:_P!2>P[_`$!([;QUI-IHO@JSLK*/9$MXI)/+.VQ\LQ[D_P#UN@H`
M\SHHHH`****`"O:_`7_(EZ?_`-M/_1C5XI7M?@+_`)$O3_\`MI_Z,:@#HZ**
M*0!1110`4444`%%%%`!1110`4444`%%%%`'SC1113`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KZ.KYQKZ.I`%%%%`!11
M10!\XT444P"BBB@`HHHH`]K\!?\`(EZ?_P!M/_1C5T=<YX"_Y$O3_P#MI_Z,
M:NCI`%%%%`!1110`445Y?XV\;?;/,TK2I?\`1N5GN%/^M]54_P!WU/?Z=0"?
MQ9\0'\V73]%D7R]I22['4G_IF>PZC=[\8P"?.J**8!1110`444Z.-YI4BB1G
MD=@JJHR6)Z`#N:`&T5WUC\+KN:V62]U".VE//E)'YF!@=3D<YR.,CCK5G_A5
M/_4:_P#)7_[.@#SBBO1_^%4_]1K_`,E?_LZ/^%4_]1K_`,E?_LZ`/.**[7_A
M6&M_\_6G_P#?Q_\`XBC_`(5AK?\`S]:?_P!_'_\`B*`.*HKM?^%8:W_S]:?_
M`-_'_P#B*ANOAOK]O$'B%K<L6QLBEP0/7Y@HQ^/>@#D**Z3_`(0+Q+_T#?\`
MR/'_`/%4?\(%XE_Z!O\`Y'C_`/BJ`.;HK6N/"^NVT[0R:3>%EQDQQ&1>F>&7
M(/YUDT`%%%%`!1110`4444`%:WA_Q!=^'=0%Q;G?&V!-"3A9%_H1V/;Z$@Y-
M%`'T'IFI6^KZ;!?VI8PS+E=PP00<$'W!!%6Z\B^'WB!M,U8:=,<VMZX49)^2
M3HI`'J<`_@<\5Z[2`****`.%^(/A?[=;'5[-(UN+="UP.AD0#KGIE0#[D=^`
M*\KKZ.KR_P`;>"?L?F:KI47^C<M/;J/]5ZLH_N^H[?3H`<#1113`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"I[.SN+^[BM;6)I9Y6VHB]2?Z#W[5;T
M;0M0UZY,%A#OV8,DC'"Q@G&2?Z#)X.`<5[#X?\+Z?X=@'V=-]TR!9;AOO/SG
M@?PC/8>@SG&:`,>V\*V_ASP?JK-MEOY;*7SI@.`-A^5?1?Y]3V`\DKWSQ#_R
M+6J_]><W_H!KP.@`HHHH`****`/6?AA_R+5S_P!?C?\`H"5VM<5\,/\`D6KG
M_K\;_P!`2NUI`%%%%`!1110!\XT444P"BBB@`HHHH`]K\!?\B7I__;3_`-&-
M71USG@+_`)$O3_\`MI_Z,:NCI`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`'.>/?^1+U#_MG_P"C%KQ2O:_'O_(EZA_VS_\`1BUXI3`****`"BBB@`KZ
M.KYQKZ.I`%%%%`!1110`4444`%%%%`'DGCGPF^E7<FI64*C3I6&Y8Q@0,>Q'
M]TGH>@SCCC/&5]&21I-$\4J*\;J596&0P/4$=Q7DGB[P3/I$[7>G123:>V6*
MJ"S08&2#_LX_B_`^I8''4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!70^%?"MQXCN]S;HK")OWTP')/]U?5OY=3V!V?"_P^GOMEYJZR6]NK\6S*
M5>0#KGNHSCW(STX->I1QI#$D42*D:*%55&`H'0`=A0!!8Z?::9;+;V5O'!$/
MX4&,G`&2>YP!R>:Y/XG_`/(M6W_7XO\`Z`]=K7%?$_\`Y%JV_P"OQ?\`T!Z0
M'DU%%%,`HHHH`*]K\!?\B7I__;3_`-&-7BE>U^`O^1+T_P#[:?\`HQJ`.CHH
MHI`%%%%`!1110`4444`%%%%`!1110`4444`>!Z]I,NBZS<V4D<B(KDPF3!+Q
MY.ULC@Y'ZY':LVO<?$?A6P\1Q*9]T-S&I$<\8&0.>&'=<\X_(C)KR_4O!&OZ
M:QS9-<Q[@HDM?W@)(ST'S`=LD#^5,#GJ*TO^$>UO_H#ZA_X#/_A1_P`(]K?_
M`$!]0_\``9_\*`,VBM+_`(1[6_\`H#ZA_P"`S_X4?\(]K?\`T!]0_P#`9_\`
M"@#-HK2_X1[6_P#H#ZA_X#/_`(4?\(]K?_0'U#_P&?\`PH`S:*TO^$>UO_H#
MZA_X#/\`X4?\(]K?_0'U#_P&?_"@#-HK2_X1[6_^@/J'_@,_^%'_``CVM_\`
M0'U#_P`!G_PH`S:*TO\`A'M;_P"@/J'_`(#/_A1_PCVM_P#0'U#_`,!G_P`*
M`,VBM+_A'M;_`.@/J'_@,_\`A1_PCVM_]`?4/_`9_P#"@#-HK2_X1[6_^@/J
M'_@,_P#A1_PCVM_]`?4/_`9_\*`,VBM+_A'M;_Z`^H?^`S_X4?\`"/:W_P!`
M?4/_``&?_"@#-HK2_P"$>UO_`*`^H?\`@,_^%'_"/:W_`-`?4/\`P&?_``H`
MS:*TO^$>UO\`Z`^H?^`S_P"%'_"/:W_T!]0_\!G_`,*`#P_;_:_$6FPF'SE:
MYCWQ[=P*A@6R/3&<^U>^5Y_X"\(7%A<'5=3@:*95`MHR_(##YF8#H<'`!Z<Y
M'2O0*0!1110`4444`?.-%=5XH\%W^D7=Q<6MNTVFEBZ/'EC$O)PPR3@`?>Z=
M.<G%<K3`****`"BBM#3=#U/5V`L+&:92Q7>%P@(&<%CP#CU/<4`>M^`O^1+T
M_P#[:?\`HQJZ.LW0-+_L;0K33RVYHD^<YR"Q)9L<#C)./:M*D`4444`%%%<]
MXR\0'0-$:2!U%Y.WEP`@'![M@GH!]>2N1S0!R_Q`\6/YKZ+I\R^7MQ=2(>2>
M\>>P]<>N.,$'SJBBF`4444`%%%.CC>:5(HD9Y'8*JJ,EB>@`[F@"6SL[B_NX
MK6UB:6>5MJ(O4G^@]^U>O^%_!=IX?V74K?:-0*8:0_=C)Z[!CTXR>?IDBF^"
MO"I\/VCW%UM:_N%&\``B)?[H/<^O;@>F3U5(`HHHH`****`"BBB@`HHHH`**
M**`"H+JSM;Z(17=M#<1AMP66,.`?7![\FIZ*`.,U+X:Z/=*39/-92;0``WF)
MG/)(;DG''WAV_'S_`%KPIJ^A9>ZM]]N/^7B'YD[=3U7D@<@9/3->YTV2-)HG
MBE17C=2K*PR&!Z@CN*`/G.BN^\;>"?L?F:KI47^C<M/;J/\`5>K*/[OJ.WTZ
M<#3`****`"BBB@`KW;PMJYUKP[:WDC*9]I2;#`G>O!)QC!/#8_VA7A->A_"R
M^VW.H:>S2'>BS(,_*N#M;\3N7\O84`>ET444@"BBB@#A?%'P^@OM]YI"QV]P
MJ<VRJ%20CICLIQGV)QTY->97EG<6%W+:W4313Q-M=&Z@_P!1[]Z^AZI:EI&G
MZQ`(=0M(YU'W2PPR\@\,.1T'0\T`?/U%>@:M\,+B-FDTFZ66,*3Y5P=KY`'`
M8#!).>NW''UKBK_2[_2Y?+OK2:W8L54R(0&(Z[3T(Z<CUI@5****`"BBB@`H
MHHH`****`"BI[6SNKZ4Q6EM-<2!=Q6*,N0/7`[<BNQT?X:ZC<RA]4=;.%6Y1
M6#R,..F.`",\Y/(Z4`<3'&\TJ11(SR.P5549+$]`!W-=QX?^'%S?(+C5WDLX
MC@K"H'F,",Y/7;R1P03UX%=YH?AC3/#ZL;*)C,Z[7GE;<[#.<>@'T`S@9SBM
MBD!6L=/M-,MEM[*WC@B'\*#&3@#)/<X`Y/-6:**`,WQ#_P`BUJO_`%YS?^@&
MO`Z^BKBWBN[:6WG7=%*AC=<D94C!&1[5X3K'A[4]"E*WULRQEL+,OS1MUQAO
M4X)P<'':@#+HHHI@%%%6[#2[_5)?+L;2:X8,%8QH2%)Z;CT`Z\GTH`].^&'_
M`"+5S_U^-_Z`E=K63X:T;^P="M[%C&TJY:5XUP&8G/XX&!D]@.G2M:D`4444
M`%%%%`'SC175>*/!=_I%W<7%K;M-II8NCQY8Q+R<,,DX`'WNG3G)Q7*TP"BB
MB@`HHK0TW0]3U=@+"QFF4L5WA<("!G!8\`X]3W%`'K?@+_D2]/\`^VG_`*,:
MNCK-T#2_[&T*TT\MN:)/G.<@L26;'`XR3CVK2I`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`'.>/?^1+U#_MG_Z,6O%*]Z\1Z4^M:!=Z?%(L<DJC:S#(
MR&#`'V.,9_G7BNI:'J>D,1?V,T*A@N\KE"2,X##@G'H>QI@9]%%%`!1110`5
M]'5X[X3\'ZAJ6H6MY<6WE:>CK(S3IQ*!@[0IZA@>O3&>O2O8J0!1110`4444
M`%%%%`!1110`4444`>?^)?AREPSW>B%8Y68L]LYPAXZ)QP<]CQSU`&*\UN+>
M>TG:&XADAE7&Z.12K#(SR#[5]%5FZSH6GZ];""_AW[,F.13AHR1C(/\`0Y'`
MR#B@#P.BNZU;X9ZA;O))ID\=U%U6.0[).O3^Z<#'.1GGBN,NK.ZL91%=VTUO
M(5W!98RA(]<'MP:8$%%%%`!1110`4444`%%%%`!16IIOAS6-64/9:?-)&5+"
M0C8A`.#AFP"<]L^OI7>:+\,[:#$NL3_:7_YXPDJ@Z]6X8]CQC!'>@#S_`$G1
M;_6[M;>Q@9SN`>0@[(P<\L>PX/UQQDUZIX:\#V&B*EQ<A;J_V@EW`*1L#GY`
M1P>G)YXXQDBNFM[>"T@6&WACAB7.V.-0JC)SP![U)2`****`"N*^)_\`R+5M
M_P!?B_\`H#UVM8_B?0QX@T26R#*DP820NV<*X]<=B"1WQG.#B@#PFBK=_I=_
MI<OEWUI-;L6*J9$(#$==IZ$=.1ZU4I@%%%%`!7M?@+_D2]/_`.VG_HQJ\ATW
M2-0UB<PZ?:23L/O%1A5X)Y8\#H>IYKV_0-+_`+&T*TT\MN:)/G.<@L26;'`X
MR3CVH`TJ***0!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!5:[T^RO]GVRSM[C9G9YT2OMSUQD<=!5FB@#-_X1[1?^@/I__@,G^%'_
M``CVB_\`0'T__P`!D_PK2HH`I6^C:7:3K-;Z;9PRKG;)'`JL,C'!`]*NT44`
M%%%%`!1110`5XAXSU9=7\37,T4F^WBQ#">,;5ZD$=06+$'T->K^*[]]-\+ZA
M=1;O,$>Q2K;2I8A0P/J-V?PKPF@`HHHI@%%%%`!7H?PX\-Q7&[6KR'<(WVVH
M8'&X=7QCG!P`<\$'N!7!V=J]]?6]I$5$D\BQ*6/`+'`S[<U[]I]C!IFGP65N
MN(H4"+P,GW..Y/)]S0!9HHHI`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`#9(TFB>*5%>-U*LK#(8'J".XKPOQ3I(T7Q%=6<:L(-P>'*D#8W(`SG('*Y
M_P!DU[M7FGQ4MXEN=,N`O[V1)(V;)Y52I`Q]6;\Z`//****8!1110`5U'P^N
M)8?&-K'&V%F21)!@<KM+8_-0?PKEZZ3P%_R.FG_]M/\`T6U`'M5%%%(`HHHH
M`****`"BBB@#"NO!OAZ\E$DNEPJP7;B(M$,?12!GGK6!=?"W3GB`M-0NHI-W
M+2A9!CTP`O/3G-=Y10!YI<?"N=8&-OJT<DO&U9("BGGN03CCVJC_`,*PUO\`
MY^M/_P"_C_\`Q%>LT4`>3?\`"L-;_P"?K3_^_C__`!%2V_PNU1IU%Q?6<<7.
MYH]SL..P(&>?>O5**`//;?X5P+.IN-6DDBYW+'`$8\=B2<<^U;5C\/\`P_9;
M2]O)=.K[PUQ(3Z<8&%(X[@]:ZBB@".WMX+2!8;>&.&)<[8XU"J,G/`'O4E%%
M`!1110`4444`%%%%`%"30M(FE>672K%Y'8LS-;H2Q/4DXY-,_P"$>T7_`*`^
MG_\`@,G^%:5%`&;_`,(]HO\`T!]/_P#`9/\`"M".-(8DBB14C10JJHP%`Z`#
ML*=10`4444`%%%%`!1110`56N]/LK_9]LL[>XV9V>=$K[<]<9''059HH`S?^
M$>T7_H#Z?_X#)_A1_P`(]HO_`$!]/_\``9/\*TJ*`*$>A:1#*DL6E6*2(P96
M6W0%2.A!QP:OT44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`4)-"TB:5Y9=*L7D=BS,UNA+$]23CDTS_`(1[1?\`H#Z?_P"`R?X5I44`
M9O\`PCVB_P#0'T__`,!D_P`*LVFGV5AO^QV=O;[\;_)B5-V.F<#GJ:LT4`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!4=Q;P7<#0W$,<T38W1R*&4X.
M>0?>I**`.<O_``+X?O\`S&^Q?9Y7Q\]NQ3;C'1?NCIZ?KS6%=?"RU>4&TU2:
M*/;RLL0D.?7(*\=.,5Z!10!Y;=?"W44E`M-0M98]O+2AHSGTP`W'3G-0?\*P
MUO\`Y^M/_P"_C_\`Q%>LT4`>3?\`"L-;_P"?K3_^_C__`!%6;3X67K[_`+9J
M5O#C&SR4:3/KG.W';UKU"B@#@[7X6Z<D1%WJ%U+)NX:(+&,>F"&YZ\YKI+#P
MIH6FR^;:Z;")-P8-)F0J1T*EB=I^E;%%`!1110`4444`%%%%`!1110`50DT+
M2)I7EETJQ>1V+,S6Z$L3U)..35^B@#-_X1[1?^@/I_\`X#)_A3X]"TB&5)8M
M*L4D1@RLMN@*D="#C@U?HH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`.#^*5TB:
M18VA#>9+.95..,*I!S[_`#C]:\MKT#XIW2/?:=:`-YD4;RL<<88@#'O\A_2O
M/Z8!1110`4444`=9\.;3[3XMCEW[?LT+RXQG=D;,>WW\_A7L5>6_"V!&U>^G
M,RB1(`BQ=V#,"6'/0;0/^!#\?4J0!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%><?%;_F$?]MO_9*]'KROXGWWG:S:62M&RV\)<[3E@SGD'\%4
M_C[T`<+1113`****`"ND\!?\CII__;3_`-%M7-UU7P[M7N/%\$J%0MO')*^3
MR05V<>^7'ZT`>R4444@"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@#R;XG_\`(RVW_7FO_H;UQ5>C_%;_`)A'_;;_`-DKSBF`4444`%%%%`'8
M_#2XBA\4O'(V&FMG2,8/+95L?DI/X5Z[7SUI]]/IFH07MNV)87#KR<'V..Q'
M!]C7OFGWT&IZ?!>V[9BF0.O(R/8X[@\'W%("S1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`-DD2&)Y975(T4LS,<!0.I)["O`]<U(ZOK=Y?DL5FD
M)3<`"$'"@XXR%`%=S\0/%B>4^BZ?,WF;L74B'@#O'GN?7'ICG)`\VI@%%%%`
M!1110`5Z/\++#_D(:B\7]V".3=_P)QC/^YSCZ=Z\XKW/PEIG]D^&;*W9-LK)
MYLN8]C;FYPP]0"%Y_N_A0!MT444@"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@#D_B-:?:?"4DN_;]FF27&,[LG9CV^_G\*\=KZ'O+5+ZQN+2
M4L(YXVB8J>0&&#CWYKP'4+&?3-0GLKA<2PN4;@X/N,]B.1[&F!6HHHH`****
M`"NF\)>+7\-RRQ2PM/:3,I90^"A'5E'0G'4<9P.1BN9HH`^A[.\M[^TBNK65
M98)5W(Z]"/Z'V[5/7@.DZU?Z)=K<6,[(=P+QDG9(!GAAW')^F>,&O0M)^)ME
M<,L6J6S6K;1F:,ET)P<DC&0,XP!NZ^V:0'>454L-4L-4B\RQNX;A0H9A&X)4
M'IN'4'KP?2K=`!1110`4444`%%%%`!1110`45'<7$%I`TUQ-'#$N-TDC!5&3
MCDGWKE-6^(FCV"LEF6OYPQ7;'\J`@@<N1R.N"`<X_&@#KZ\]\7>/HE@:PT2?
M?(V5ENDR`@SC"'N3_>'`'3DY')>(/%VI>('*2/Y%H,@6\3':1G(W?WCP/;C@
M"L"@`HHHI@%%%%`!113HXWFE2*)&>1V"JJC)8GH`.YH`Z+P3H?\`;7B"/S8]
MUI;8EFR,AL?=4\$<GL>H#5[56%X3T%-!T2*)HU6[E4/<MCDM_=)R>%SCCCJ>
MYK=I`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5YU\
M2O#Y=4URW1<(HCNN0#C("MTY/.#S_=XP#7HM-DC2:)XI45XW4JRL,A@>H([B
M@#YSHKK_`!EX-?0Y6O;)6?37;D=3`3V/JOH?P/.">0I@%%%%`!1110`4444`
M.CD>&5)8G9)$8,K*<%2.A![&MNU\9>(;.(QQ:I,REMV90LIS]6!...E85%`'
M:V_Q.UF/REFM[.95P'.QE9P.O(.`3],>U:7_``M;_J"_^37_`-A7G%%`'J5K
M\4M.>(F[T^ZBDW<+$5D&/7)*\]>,5/\`\+/T7_GUU#_OVG_Q=>344`>L_P#"
MS]%_Y]=0_P"_:?\`Q=9\GQ502N(M'9HPQVLUQM)'8D;3@^V37FU%`'?7?Q3O
M7V?8]-MX<9W^<[29],8VX[^M9-]\0/$%[N"7$=JC)L*V\8'KSDY8'GL1TKEZ
M*`)[J\NKZ42W=S-<2!=H:60N0/3)[<FH***`"BBB@`HHHH`****`"O4O`W@U
M].:/5]15DNRI\B`\&,$8);_:()X[9YYZ5O"?P_3RHM0UJ-O,W!X[0]`/^F@[
MGH=OMSG)`]%I`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`#9(TFB>*5%>-U*LK#(8'J".XKR_P`2_#NXM6>ZT8-<0%BQ
MMOXXQC/!)^<=>.O3KR:]2HH`^<:*]M\0>#=,U]GGD5H+PK@7$?4X!`W#H1T]
M#P!D5YUJW@'6]->1H8/MMNO(D@Y8C.!E/O9Z$XR!GK3`Y>BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BKNFZ1J&L3F'3[22=A]XJ,*O!/
M+'@=#U/-=YH_PP"2B36+I9%5N(;8G##CJQ`..HP`/K0!PVDZ+?ZW=K;V,#.=
MP#R$'9&#GECV'!^N.,FO5/#7@>PT14N+D+=7^T$NX!2-@<_(".#TY//'&,D5
MT=G9V]A:16MK$L4$2[41>@']3[]ZGI`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`%#4M#TS5U(O[
M&&9BH7>5PX`.<!AR!GT/<UR&I_#"TEW2:9>20-\Q$4PWKG^%01@@=LG<?Z]]
M10!XS??#_P`066XI;QW2*F\M;R`^O&#AB>.P/6L"[T^]L-GVRSN+??G9YT3)
MNQUQD<]17T+10!\XT5]`W&C:7=SM-<:;9S2MC=))`K,<#')(]*S;CP3X<N9V
MFDTN,,V,B-VC7ICA5(`_*F!XA17H?CSPSI&C:'!<:?:>3*URL9;S';*E6.,$
MGN!7GE`!1110`4444`%%>NZ-X*\/7>AZ?<3Z?NEEMHY';SI!EBH).`WK6S:^
M%-`LXC'%I-JREMV94\TY^K9...E`'A-;%KX4U^\E,<6DW2L%W9E3RACZM@9Y
MZ5[E;V\%I`L-O#'#$N=L<:A5&3G@#WJ2D!Y78_##4IMK7MY;VRE,X0&1@W'R
MD<#UY!/2NNTWP%H&G,'-LUW(&)#73;P`1C&T`*1]1_2NFHH`;'&D,211(J1H
MH5548"@=`!V%.HHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
>HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
